Interferon	O
augments	O
PML	B-protein
and	O
PML/RAR	B-protein
alpha	I-protein
expression	O
in	O
normal	O
myeloid	B-cell_type
and	O
acute	B-cell_type
promyelocytic	I-cell_type
cells	I-cell_type
and	O
cooperates	O
with	O
all-trans	O
retinoic	O
acid	O
to	O
induce	O
maturation	O
of	O
a	O
retinoid-resistant	B-cell_line
promyelocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
PML	B-DNA
gene	I-DNA
is	O
fused	O
to	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
(	O
RAR	B-DNA
alpha	I-DNA
)	O
in	O
the	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
15	O
;	O
17	O
translocation	O
.	O

PML	B-protein
is	O
expressed	O
in	O
diverse	O
tissues	O
and	O
cell	O
lines	O
and	O
localized	O
in	O
the	O
nucleus	O
with	O
a	O
typical	O
speckled	O
pattern	O
.	O

In	O
the	O
bone	O
marrow	O
,	O
it	O
is	O
preferentially	O
expressed	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

PML	B-protein
appears	O
to	O
be	O
transcriptionally	O
regulated	O
by	O
class	B-protein
I	I-protein
and	I-protein
II	I-protein
interferons	I-protein
,	O
which	O
raises	O
the	O
possibility	O
that	O
interferons	O
modulate	O
the	O
function	O
and	O
growth	O
and	O
differentiation	O
potential	O
of	O
normal	O
myeloid	B-cell_type
cells	I-cell_type
and	O
precursors	O
by	O
activating	O
PML	B-protein
-dependent	O
pathways	O
.	O

Similarly	O
,	O
interferons	O
could	O
act	O
on	O
APL	B-cell_type
cells	I-cell_type
,	O
alone	O
or	O
in	O
combination	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
especially	O
if	O
the	O
PML/RAR	B-RNA
alpha	I-RNA
fusion	I-RNA
transcript	I-RNA
that	O
results	O
from	O
the	O
t	B-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
is	O
induced	O
by	O
interferon	B-protein
.	O

We	O
report	O
here	O
that	O
PML	B-protein
is	O
expressed	O
at	O
low	O
levels	O
or	O
not	O
expressed	O
in	O
normal	O
circulating	O
human	B-cell_type
monocytes	I-cell_type
,	O
lymphocytes	B-cell_type
,	O
and	O
polymorphonucleate	B-cell_type
cells	I-cell_type
,	O
but	O
is	O
markedly	O
induced	O
by	O
interferon	B-protein
;	O
that	O
PML	B-protein
and	O
PML/RAR	B-protein
alpha	I-protein
expression	O
is	O
augmented	O
by	O
interferon	B-protein
in	O
the	O
NB4	B-cell_line
APL	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
carries	O
the	O
t	B-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
,	O
and	O
in	O
APL	B-cell_type
blasts	I-cell_type
from	O
patients	O
;	O
that	O
interferon	B-protein
inhibits	O
growth	O
and	O
survival	O
of	O
NB4	O
APL	B-cell_type
cells	I-cell_type
in	O
cooperation	O
with	O
RA	O
;	O
that	O
interferons	O
alone	O
have	O
minimal	O
maturation	O
effect	O
on	O
NB4	B-cell_line
cells	I-cell_line
;	O
and	O
,	O
finally	O
,	O
that	O
interferon	B-protein
gamma	I-protein
,	I-protein
but	I-protein
not	I-protein
alpha	I-protein
or	I-protein
beta	I-protein
,	O
induces	O
maturation	O
and	O
growth	O
suppression	O
of	O
NB4	B-cell_line
cells	I-cell_line
with	O
de	O
novo	O
retinoid	O
resistance	O
,	O
and	O
partially	O
restores	O
RA	O
response	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Interferon	NULL
Augments	NULL
PML	NULL
and	NULL
PML/RARa	NULL
Expression	NULL
in	NULL
Normal	NULL
Myeloid	NULL
and	NULL
Acute	NULL
Promyelocytic	NULL
Cells	NULL
and	NULL
Cooperates	NULL
With	NULL
All-trans	NULL
Retinoic	NULL
Acid	NULL
to	NULL
Induce	NULL
Maturation	NULL
of	NULL
a	NULL
Retinoid-Resistant	NULL
Promyelocytic	NULL
Cell	NULL
Line	NULL
By	NULL
Kathryn	NULL
Nason-Burchenal	NULL
,	NULL
Domenica	NULL
Gandini	NULL
,	NULL
Marina	NULL
Botto	NULL
,	NULL
Janet	NULL
Allopenna	NULL
,	NULL
James	NULL
R.C	NULL
.	NULL

Seale	NULL
,	NULL
Nicholas	NULL
C.P	NULL
.	NULL

Cross	NULL
,	NULL
John	NULL
M.	NULL
Goldman	NULL
,	NULL
Ethan	NULL
Dmitrovsky	NULL
,	NULL
and	NULL
Pier	NULL
Paolo	NULL
Pandolfi	NULL
The	NULL
PML	NULL
gene	NULL
is	NULL
fused	NULL
to	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
gene	NULL
(	NULL
RARa	NULL
)	NULL
in	NULL
the	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
{	NULL
(	NULL
APL	NULL
)	NULL
15	NULL
;	NULL
17	NULL
translocation	NULL
.	NULL

PML	NULL
is	NULL
expressed	NULL
in	NULL
diverse	NULL
tissues	NULL
and	NULL
cell	NULL
lines	NULL
and	NULL
localized	NULL
in	NULL
the	NULL
nucleus	NULL
with	NULL
a	NULL
typical	NULL
speckled	NULL
pattern	NULL
.	NULL

In	NULL
the	NULL
bone	NULL
marrow	NULL
,	NULL
it	NULL
is	NULL
preferentially	NULL
expressed	NULL
in	NULL
myeloid	NULL
cells	NULL
.	NULL

PML	NULL
appears	NULL
to	NULL
be	NULL
transcriptionally	NULL
regulated	NULL
by	NULL
class	NULL
|	NULL
and	NULL
iI	NULL
interferons	NULL
,	NULL
which	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
interferons	NULL
modulate	NULL
the	NULL
function	NULL
and	NULL
growth	NULL
and	NULL
differentiation	NULL
potential	NULL
of	NULL
normal	NULL
myeloid	NULL
cells	NULL
and	NULL
precursors	NULL
by	NULL
activating	NULL
PML-dependent	NULL
pathways	NULL
.	NULL

Similarly	NULL
,	NULL
interferons	NULL
could	NULL
act	NULL
on	NULL
APL	NULL
cells	NULL
,	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
,	NULL
especially	NULL
if	NULL
the	NULL
PML/RAR	NULL
«	NULL
fusion	NULL
transcript	NULL
that	NULL
results	NULL
from	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
is	NULL
induced	NULL
by	NULL
inter	NULL
CUTE	NULL
PROMYELOCYTIC	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
,	NULL
the	NULL
M3	NULL
subtype	NULL
in	NULL
the	NULL
French-	NULL
American-British	NULL
(	NULL
FAB	NULL
)	NULL
classi-fication	NULL
,	NULL
represents	NULL
greater	NULL
than	NULL
10	NULL
%	NULL
of	NULL
all	NULL
the	NULL
myelogenous	NULL
leukemias	NULL
in	NULL
adults	NULL
.	NULL

APL	NULL
is	NULL
characterized	NULL
by	NULL
the	NULL
expansion	NULL
,	NULL
in	NULL
bone	NULL
marrow	NULL
,	NULL
of	NULL
abnormal	NULL
promyelocytes	NULL
.	NULL

'~	NULL
APL	NULL
patients	NULL
often	NULL
respond	NULL
to	NULL
chemotherapy	NULL
,	NULL
while	NULL
the	NULL
majority	NULL
of	NULL
patients	NULL
also	NULL
achieve	NULL
transient	NULL
complete	NULL
remission	NULL
following	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
treatment	NULL
.	NULL
``	NULL

''	NULL
RA	NULL
,	NULL
both	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
,	NULL
induces	NULL
terminal	NULL
differentiation	NULL
of	NULL
APL	NULL
cells	NULL
toward	NULL
mature	NULL
granulocytes	NULL
.	NULL
``	NULL

Unlike	NULL
with	NULL
other	NULL
myeloid	NULL
leukemias	NULL
,	NULL
APL	NULL
cells	NULL
are	NULL
extremely	NULL
sensitive	NULL
to	NULL
the	NULL
matura-tion-inducing	NULL
action	NULL
of	NULL
RA	NULL
.	NULL

This	NULL
exquisite	NULL
sensitivity	NULL
is	NULL
para-doxical	NULL
,	NULL
since	NULL
the	NULL
molecular	NULL
hallmark	NULL
of	NULL
the	NULL
disease	NULL
is	NULL
a	NULL
reciprocal	NULL
translocation	NULL
that	NULL
involves	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
(	NULL
RARa	NULL
)	NULL
gene	NULL
on	NULL
chromosome	NULL
17	NULL
.	NULL

RARa	NULL
is	NULL
translo-cated	NULL
to	NULL
a	NULL
gene	NULL
located	NULL
on	NULL
chromosome	NULL
15	NULL
,	NULL
initially	NULL
designated	NULL
myl	NULL
,	NULL
and	NULL
subsequently	NULL
renamed	NULL
PML	NULL
.	NULL
``	NULL

Two	NULL
fusion	NULL
From	NULL
the	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
and	NULL
Developmental	NULL
Biology	NULL
,	NULL
Department	NULL
of	NULL
Human	NULL
Genetics	NULL
,	NULL
and	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Medicine	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Memorial	NULL
Sloan-Kettering	NULL
Cancer	NULL
Center	NULL
;	NULL
Molecular	NULL
Biology	NULL
Program	NULL
,	NULL
and	NULL
Molecular	NULL
Pharmacology	NULL
and	NULL
Therapeutics	NULL
Program	NULL
,	NULL
Sloan-Kettering	NULL
Institute	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
;	NULL
and	NULL
the	NULL
Department	NULL
of	NULL
Hematology	NULL
,	NULL
Royal	NULL
Postgraduate	NULL
Medical	NULL
School	NULL
(	NULL
RPMS	NULL
)	NULL
,	NULL
and	NULL
Leukemia	NULL
Research	NULL
Fund	NULL
Center	NULL
for	NULL
Adult	NULL
Leukemia	NULL
,	NULL
and	NULL
Rheumatology	NULL
Unit	NULL
,	NULL
RPMS	NULL
,	NULL
Hammersmith	NULL
Hospital	NULL
,	NULL
London	NULL
,	NULL
UK	NULL
.	NULL

Submitted	NULL
March	NULL
14	NULL
,	NULL
1996	NULL
;	NULL
accepted	NULL
July	NULL
5	NULL
,	NULL
1996	NULL
.	NULL

K.N.-B	NULL
.	NULL

and	NULL
D.G	NULL
.	NULL

contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
.	NULL

Supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
NIH	NULL
)	NULL
Grant	NULL
No	NULL
.	NULL

IRO	NULL
!	NULL

CA6G2275-02	NULL
(	NULL
ED	NULL
.	NULL
)	NULL

.	NULL

K.N.-B	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
NIH	NULL
National	NULL
Research	NULL
Service	NULL
Award	NULL
1F32CA61646-0141	NULL
and	NULL
2PO1-CA29502-1442	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Pier	NULL
Paolo	NULL
Pandolfi	NULL
,	NULL
MD	NULL
,	NULL
PhD	NULL
,	NULL
Department	NULL
of	NULL
Human	NULL
Genetics	NULL
,	NULL
Memorial	NULL
Sloan-Kettering	NULL
Cancer	NULL
Center	NULL
,	NULL
1275	NULL
York	NULL
Ave	NULL
,	NULL
Box	NULL
110	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
10021	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-497	NULL
1/96/8810-0013	NULL
$	NULL
3.00/0	NULL
3926	NULL
feron	NULL
.	NULL

We	NULL
report	NULL
here	NULL
that	NULL
PML	NULL
is	NULL
expressed	NULL
at	NULL
low	NULL
levels	NULL
or	NULL
not	NULL
expressed	NULL
in	NULL
normal	NULL
circulating	NULL
human	NULL
monocytes	NULL
,	NULL
lymphocytes	NULL
,	NULL
and	NULL
polymorphonucleate	NULL
cells	NULL
,	NULL
but	NULL
is	NULL
markedly	NULL
induced	NULL
by	NULL
interferon	NULL
;	NULL
that	NULL
PML	NULL
and	NULL
PML/RARa	NULL
expression	NULL
is	NULL
augmented	NULL
by	NULL
interferon	NULL
in	NULL
the	NULL
NB4	NULL
APL	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
carries	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
}	NULL
,	NULL
and	NULL
in	NULL
APL	NULL
blasts	NULL
from	NULL
patients	NULL
;	NULL
that	NULL
interferon	NULL
inhibits	NULL
growth	NULL
and	NULL
survival	NULL
of	NULL
NB4	NULL
APL	NULL
cells	NULL
in	NULL
cooperation	NULL
with	NULL
RA	NULL
;	NULL
that	NULL
interferons	NULL
alone	NULL
have	NULL
minimal	NULL
maturation	NULL
effect	NULL
on	NULL
NB4	NULL
cells	NULL
;	NULL
and	NULL
,	NULL
finally	NULL
,	NULL
that	NULL
interferon	NULL
y	NULL
,	NULL
but	NULL
not	NULL
a	NULL
or	NULL
,	NULL
induces	NULL
maturation	NULL
and	NULL
growth	NULL
suppression	NULL
of	NULL
NB4	NULL
cells	NULL
with	NULL
de	NULL
novo	NULL
retinoid	NULL
resistance	NULL
,	NULL
and	NULL
partially	NULL
restores	NULL
RA	NULL
response	NULL
.	NULL

©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

transcripts	NULL
can	NULL
be	NULL
expressed	NULL
:	NULL
PML/RARa	NULL
and	NULL
RARa/	NULL
PML	NULL
.	NULL

'*'°	NULL
PML/RARa	NULL
is	NULL
expressed	NULL
in	NULL
all	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
-containing	NULL
APL	NULL
cases	NULL
and	NULL
,	NULL
in	NULL
the	NULL
leukemic	NULL
blasts	NULL
,	NULL
coexists	NULL
with	NULL
a	NULL
truncated	NULL
form	NULL
of	NULL
PML	NULL
,	NULL
referred	NULL
to	NULL
as	NULL
aberrant	NULL
PML	NULL
.	NULL

RARa/	NULL
PML	NULL
is	NULL
expressed	NULL
in	NULL
only	NULL
70	NULL
%	NULL
of	NULL
cases	NULL
.	NULL
``	NULL

''	NULL
The	NULL
PML/RARa	NULL
protein	NULL
retains	NULL
most	NULL
of	NULL
the	NULL
putative	NULL
functional	NULL
domains	NULL
of	NULL
the	NULL
PML	NULL
protein	NULL
and	NULL
the	NULL
DNA	NULL
and	NULL
ligand-binding	NULL
domain	NULL
of	NULL
RARa	NULL
.	NULL

PML/RARa	NULL
can	NULL
heterodimerize	NULL
with	NULL
RXR	NULL
and	NULL
PML/RARa	NULL
has	NULL
the	NULL
potential	NULL
to	NULL
interfere	NULL
with	NULL
both	NULL
PML	NULL
and	NULL
RARa	NULL
endogenous	NULL
signaling	NULL
pathways	NULL
and	NULL
,	NULL
in	NULL
vitro	NULL
,	NULL
blocks	NULL
terminal	NULL
differentiation	NULL
of	NULL
hematopoietic	NULL
precursor	NULL
cell	NULL
lines	NULL
and	NULL
promotes	NULL
cell	NULL
growth	NULL
by	NULL
inhibiting	NULL
apo-ptotic	NULL
cell	NULL
death	NULL
.	NULL
``	NULL

''	NULL
RARa	NULL
is	NULL
a	NULL
transcription	NULL
factor	NULL
and	NULL
member	NULL
of	NULL
the	NULL
nuclear	NULL
hormone	NULL
receptor	NULL
superfamily	NULL
,	NULL
implicated	NULL
in	NULL
regulating	NULL
aspects	NULL
of	NULL
development	NULL
and	NULL
differentiation	NULL
.	NULL
``	NULL

PML	NULL
is	NULL
a	NULL
nuclear	NULL
protein	NULL
whose	NULL
normal	NULL
function	NULL
is	NULL
at	NULL
present	NULL
under	NULL
active	NULL
study	NULL
.	NULL
``	NULL

''	NULL
Recently	NULL
,	NULL
we	NULL
found	NULL
that	NULL
PML	NULL
expression	NULL
is	NULL
specifically	NULL
transcriptionally	NULL
regulated	NULL
by	NULL
class	NULL
I	NULL
and	NULL
II	NULL
interferon	NULL
treatment	NULL
of	NULL
diverse	NULL
cell	NULL
lines	NULL
.	NULL
``	NULL

''	NULL
This	NULL
finding	NULL
prompted	NULL
us	NULL
to	NULL
investigate	NULL
the	NULL
following	NULL
:	NULL
(	NULL
1	NULL
)	NULL
if	NULL
this	NULL
regulation	NULL
was	NULL
occurring	NULL
in	NULL
normal	NULL
circulating	NULL
myeloid	NULL
cells	NULL
;	NULL
(	NULL
2	NULL
)	NULL
if	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
PML	NULL
and	NULL
PML/RARa	NULL
proteins	NULL
was	NULL
affected	NULL
by	NULL
interferon	NULL
in	NULL
NB4	NULL
cells	NULL
,	NULL
the	NULL
sole	NULL
APL	NULL
cell	NULL
line	NULL
carrying	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
,	NULL
or	NULL
in	NULL
APL	NULL
blasts	NULL
from	NULL
patients	NULL
;	NULL
(	NULL
3	NULL
)	NULL
if	NULL
interferon	NULL
influences	NULL
the	NULL
capacity	NULL
of	NULL
NB4	NULL
cells	NULL
to	NULL
grow	NULL
and	NULL
survive	NULL
before	NULL
or	NULL
after	NULL
RA	NULL
treatment	NULL
;	NULL
(	NULL
4	NULL
)	NULL
if	NULL
interferon	NULL
induces	NULL
terminal	NULL
differentiation	NULL
of	NULL
APL	NULL
cells	NULL
;	NULL
and	NULL
(	NULL
5	NULL
)	NULL
if	NULL
interferons	NULL
could	NULL
restore	NULL
RA	NULL
response	NULL
in	NULL
RA-resistant	NULL
NB4	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
purification	NULL
and	NULL
cell	NULL
culture	NULL
conditions	NULL
of	NULL
human	NULL
neutrophils	NULL
,	NULL
lymphocytes	NULL
,	NULL
and	NULL
monocytes	NULL
.	NULL

-	NULL
Peripheral	NULL
blood	NULL
from	NULL
normal	NULL
human	NULL
volunteers	NULL
was	NULL
obtained	NULL
by	NULL
venipuncture	NULL
.	NULL

Neutrophils	NULL
were	NULL
isolated	NULL
under	NULL
sterile	NULL
conditions	NULL
by	NULL
two	NULL
consecutive	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugations	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

Each	NULL
experiment	NULL
was	NULL
performed	NULL
on	NULL
cells	NULL
derived	NULL
from	NULL
a	NULL
single	NULL
donor	NULL
.	NULL

Cell	NULL
preparations	NULL
were	NULL
routinely	NULL
assessed	NULL
for	NULL
viability	NULL
(	NULL
>	NULL
95	NULL
%	NULL
)	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
and	NULL
for	NULL
contaminating	NULL
cell	NULL
types	NULL
by	NULL
Wright	NULL
staining	NULL
and	NULL
nonspecific	NULL
esterase	NULL
cytochemistry	NULL
(	NULL
a-naphthyl	NULL
acetate	NULL
esterase	NULL
staining	NULL
)	NULL
,	NULL
which	NULL
showed	NULL
that	NULL
greater	NULL
than	NULL
99	NULL
%	NULL
of	NULL
purified	NULL
cells	NULL
were	NULL
polymorphonuclear	NULL
leukocytes	NULL
(	NULL
PMN	NULL
)	NULL
.	NULL

Monocytes	NULL
were	NULL
isolated	NULL
Blood	NULL
,	NULL
Vol	NULL
88	NULL
,	NULL
No	NULL
10	NULL
(	NULL
November	NULL
15	NULL
)	NULL
,	NULL
1996	NULL
:	NULL
pp	NULL
3926-3936	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IFN	NULL
AND	NULL
RA-RESISTANCE	NULL
IN	NULL
APL	NULL
from	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
by	NULL
adherence	NULL
to	NULL
polystyrene	NULL
tissue	NULL
culture	NULL
flasks	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
37°C	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

PMN	NULL
(	NULL
10'/mL	NULL
)	NULL
and	NULL
monocytes	NULL
(	NULL
6	NULL
to	NULL
8	NULL
x	NULL
10°/mL	NULL
.	NULL
)	NULL

were	NULL
cultured	NULL
for	NULL
up	NULL
to	NULL
24	NULL
hours	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
GIBCO	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
,	NULL
2	NULL
mmol/L	NULL
L-glutamine	NULL
,	NULL
and	NULL
antibiotics	NULL
.	NULL

All	NULL
media	NULL
,	NULL
sup-plements	NULL
,	NULL
and	NULL
buffers	NULL
were	NULL
prepared	NULL
using	NULL
endotoxin-free	NULL
water	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Escherichia	NULL
coli	NULL
lipopolysac-charide	NULL
(	NULL
LPS	NULL
;	NULL
1	NULL
mg/mL	NULL
)	NULL
(	NULL
Sigma	NULL
Chemical	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
;	NULL
serotype	NULL
026.B6	NULL
)	NULL
;	NULL
interferon	NULL
y	NULL
(	NULL
20	NULL
ng/mL	NULL
,	NULL
100	NULL
U/mL	NULL
)	NULL
(	NULL
Hoffman-LaRoche	NULL
,	NULL
Nutley	NULL
,	NULL
NJ	NULL
)	NULL
or	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
(	NULL
TNF-a	NULL
;	NULL
5	NULL
ng/mL	NULL
,	NULL
800	NULL
U/	NULL
mL	NULL
)	NULL
(	NULL
Bissendorf	NULL
Biochemicals	NULL
,	NULL
Hannover	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Cell	NULL
culture	NULL
of	NULL
APL	NULL
blasts	NULL
.	NULL

APL	NULL
patients	NULL
'	NULL
mononuclear	NULL
cells	NULL
were	NULL
suspended	NULL
at	NULL
10¢/mL	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Gibco	NULL
,	NULL
Paisley	NULL
,	NULL
UK	NULL
)	NULL
,	NULL
15	NULL
%	NULL
FCS	NULL
(	NULL
Seromed	NULL
,	NULL
Berlin	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
and	NULL
cultured	NULL
at	NULL
37°C	NULL
in	NULL
humidified	NULL
air	NULL
with	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
,	NULL
for	NULL
24	NULL
hours	NULL
.	NULL

Recombinant	NULL
human	NULL
«	NULL
-interferon	NULL
2a	NULL
(	NULL
Hoffman-LaRoche	NULL
,	NULL
Nutley	NULL
,	NULL
NJ	NULL
)	NULL
and	NULL
y-interferon	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
were	NULL
both	NULL
used	NULL
at	NULL
levels	NULL
similar	NULL
to	NULL
those	NULL
achieved	NULL
by	NULL
pharmacologic	NULL
doses	NULL
of	NULL
100	NULL
U/mL	NULL
.	NULL

RNA	NULL
isolation	NULL
and	NULL
Northern	NULL
analysis	NULL
.	NULL

|	NULL
Total	NULL
cellular	NULL
RNA	NULL
was	NULL
extracted	NULL
from	NULL
cell	NULL
preparations	NULL
by	NULL
the	NULL
guanidinium-isothiocyanate-phenol-chloroform	NULL
method	NULL
,	NULL
``	NULL
``	NULL
electrophoresed	NULL
on	NULL
1	NULL
%	NULL
agarose	NULL
gels	NULL
,	NULL
blotted	NULL
onto	NULL
a	NULL
nylon	NULL
membrane	NULL
(	NULL
Nytran	NULL
;	NULL
Shleicher	NULL
&	NULL
Schuell	NULL
,	NULL
Keene	NULL
,	NULL
NH	NULL
)	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
different	NULL
cDNA	NULL
probes	NULL
labeled	NULL
with	NULL
[	NULL
P	NULL
]	NULL
by	NULL
the	NULL
random	NULL
primer	NULL
method	NULL
.	NULL
``	NULL

''	NULL
Hybridizations	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
PML	NULL
cDNA	NULL
probe	NULL
LAV1O	NULL
and	NULL
the	NULL
RARa	NULL
cDNA	NULL
probe	NULL
IT	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

``	NULL
``	NULL
>	NULL
``	NULL
A	NULL
cDNA	NULL
probe	NULL
for	NULL
P-actin	NULL
,	NULL
a	NULL
gene	NULL
constitu-tively	NULL
expressed	NULL
and	NULL
not	NULL
modulated	NULL
by	NULL
cytokine	NULL
treatment	NULL
,	NULL
was	NULL
used	NULL
as	NULL
control	NULL
for	NULL
the	NULL
amounts	NULL
of	NULL
RNA	NULL
loaded	NULL
onto	NULL
the	NULL
gels	NULL
.	NULL

RNA	NULL
was	NULL
quantified	NULL
by	NULL
optical	NULL
density	NULL
and	NULL
by	NULL
scanning	NULL
densitometry	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Immunofluorescence	NULL
microscopy	NULL
.	NULL

-	NULL
Peripheral	NULL
blood	NULL
from	NULL
normal	NULL
human	NULL
volunteers	NULL
was	NULL
obtained	NULL
by	NULL
venipuncture	NULL
.	NULL

PMNs	NULL
were	NULL
isolated	NULL
under	NULL
sterile	NULL
conditions	NULL
by	NULL
two	NULL
consecutive	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugations	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

Each	NULL
experiment	NULL
was	NULL
performed	NULL
on	NULL
cells	NULL
derived	NULL
from	NULL
a	NULL
single	NULL
donor	NULL
.	NULL

Cell	NULL
preparations	NULL
were	NULL
routinely	NULL
assessed	NULL
for	NULL
contaminating	NULL
cell	NULL
types	NULL
by	NULL
Wright	NULL
staining	NULL
,	NULL
which	NULL
showed	NULL
that	NULL
the	NULL
population	NULL
of	NULL
purified	NULL
cells	NULL
were	NULL
PMN	NULL
.	NULL

Monocytes	NULL
were	NULL
isolated	NULL
from	NULL
PBMC	NULL
by	NULL
adherence	NULL
to	NULL
polystyrene	NULL
tissue	NULL
culture	NULL
flasks	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
37°C	NULL
as	NULL
described	NULL
previously	NULL
and	NULL
lymphocytes	NULL
were	NULL
collected	NULL
as	NULL
well	NULL
.	NULL

PMN	NULL
,	NULL
lymphocytes	NULL
,	NULL
and	NULL
monocytes	NULL
were	NULL
cultured	NULL
for	NULL
24	NULL
and	NULL
48	NULL
hours	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
GIBCO	NULL
)	NULL
,	NULL
supplemented	NULL
with	NULL
30	NULL
%	NULL
heat-inactivated	NULL
FCS	NULL
,	NULL
2	NULL
mmol/L	NULL
L-glutamine	NULL
,	NULL
and	NULL
antibiotics	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
interferon	NULL
y	NULL
(	NULL
100	NULL
U/mL	NULL
)	NULL
.	NULL

The	NULL
PMN	NULL
and	NULL
lymphocytes	NULL
were	NULL
then	NULL
collected	NULL
and	NULL
subjected	NULL
to	NULL
cytospin	NULL
(	NULL
10°	NULL
cells/slide	NULL
)	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
fixed	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
4	NULL
%	NULL
paraformaldehyde	NULL
for	NULL
10	NULL
minutes	NULL
,	NULL
and	NULL
methanol	NULL
at	NULL
-20°C	NULL
for	NULL
7	NULL
minutes	NULL
.	NULL

Cells	NULL
were	NULL
subsequently	NULL
incubated	NULL
with	NULL
10	NULL
%	NULL
goat	NULL
serum	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
blocking	NULL
solution	NULL
for	NULL
1	NULL
hour	NULL
and	NULL
then	NULL
for	NULL
1	NULL
hour	NULL
with	NULL
monoclonal	NULL
antibody	NULL
(	NULL
MoAb	NULL
)	NULL
PG-M3	NULL
``	NULL
®	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
an	NULL
MoAb	NULL
raised	NULL
specifically	NULL
against	NULL
a	NULL
peptide	NULL
sequence	NULL
located	NULL
within	NULL
the	NULL
aminoterminal	NULL
region	NULL
of	NULL
the	NULL
human	NULL
PML	NULL
protein	NULL
.	NULL

The	NULL
dilution	NULL
of	NULL
the	NULL
antibody	NULL
was	NULL
1:150	NULL
.	NULL

Bound	NULL
MoAb	NULL
was	NULL
detected	NULL
using	NULL
a	NULL
rabbit	NULL
antimouse	NULL
antibody	NULL
conjugated	NULL
with	NULL
fluores-cein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
;	NULL
Sigma	NULL
)	NULL
.	NULL

A	NULL
DAPI	NULL
(	NULL
4',6-diamine-2-phenyl-indole-dihydrochloride	NULL
)	NULL
nuclear	NULL
staining	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
In-dianapolis	NULL
,	NULL
IN	NULL
)	NULL
was	NULL
also	NULL
performed	NULL
.	NULL

Specimens	NULL
were	NULL
then	NULL
analyzed	NULL
using	NULL
an	NULL
Olympus	NULL
BX60	NULL
fluorescence	NULL
microscope	NULL
(	NULL
Olympus	NULL
America	NULL
,	NULL
Lake	NULL
Success	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Protein	NULL
isolation	NULL
,	NULL
Western	NULL
analysis	NULL
,	NULL
and	NULL
antibodies	NULL
.	NULL

A	NULL
total	NULL
of	NULL
10	NULL
'	NULL
cells	NULL
was	NULL
pelleted	NULL
,	NULL
resuspended	NULL
in	NULL
1	NULL
mL	NULL
of	NULL
chilled	NULL
RIPA	NULL
lysis	NULL
buffer	NULL
(	NULL
150	NULL
mmol/L	NULL
NaCl	NULL
+	NULL
50	NULL
mmol/L	NULL
Tris	NULL
pH	NULL
8.0	NULL
+	NULL
1	NULL
%	NULL
NP-40	NULL
+	NULL
0.5	NULL
%	NULL
deoxycholate	NULL
+	NULL
0.5	NULL
ug	NULL
aprotinin	NULL
,	NULL
leupeptin	NULL
,	NULL
pepstatin	NULL
,	NULL
antitrypsin	NULL
,	NULL
chymostatin	NULL
+	NULL
1	NULL
mmol/L	NULL
phenylmethyisulfonyl	NULL
fluoride	NULL
3927	NULL
[	NULL
PMSF	NULL
]	NULL
)	NULL
,	NULL
and	NULL
left	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
minutes	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
centrifuged	NULL
at	NULL
12,000	NULL
rpm	NULL
for	NULL
2	NULL
minutes	NULL
and	NULL
the	NULL
supernatant	NULL
was	NULL
stored	NULL
on	NULL
ice	NULL
.	NULL

Protein	NULL
concentration	NULL
was	NULL
assessed	NULL
with	NULL
the	NULL
Bradford	NULL
assay	NULL
,	NULL
and	NULL
50	NULL
ug	NULL
protein	NULL
per	NULL
lane	NULL
was	NULL
run	NULL
on	NULL
a	NULL
10	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
polyacrylamide	NULL
gel	NULL
for	NULL
3.5	NULL
hours	NULL
at	NULL
100V	NULL
.	NULL

The	NULL
protein	NULL
was	NULL
electrotransferred	NULL
from	NULL
the	NULL
gel	NULL
to	NULL
supported	NULL
nitrocellulose	NULL
(	NULL
Amersham	NULL
International	NULL
,	NULL
Little	NULL
Chalfont	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

The	NULL
ECL	NULL
Western	NULL
blotting	NULL
protocol	NULL
and	NULL
kit	NULL
(	NULL
Amersham	NULL
International	NULL
)	NULL
was	NULL
used	NULL
for	NULL
antibody	NULL
labeling	NULL
and	NULL
detection	NULL
.	NULL

Blots	NULL
were	NULL
exposed	NULL
to	NULL
film	NULL
for	NULL
5	NULL
to	NULL
10	NULL
seconds	NULL
for	NULL
the	NULL
RARa	NULL
antibody	NULL
and	NULL
1	NULL
to	NULL
5	NULL
seconds	NULL
for	NULL
the	NULL
PML	NULL
antibody	NULL
.	NULL

The	NULL
films	NULL
were	NULL
scanned	NULL
with	NULL
a	NULL
BioRad	NULL
Model	NULL
GS-700	NULL
Imaging	NULL
Densitometer	NULL
(	NULL
BioRad	NULL
,	NULL
Hercules	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Relative	NULL
intensities	NULL
were	NULL
analyzed	NULL
with	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
NIH	NULL
)	NULL
Image	NULL
1.57	NULL
(	NULL
by	NULL
Wayne	NULL
Rasband	NULL
,	NULL
NIH	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
Molecular	NULL
Analyst	NULL
(	NULL
BioRad	NULL
)	NULL
software	NULL
.	NULL

The	NULL
PML	NULL
antibody	NULL
,	NULL
PML	NULL
PG-M3	NULL
was	NULL
used	NULL
at	NULL
a	NULL
1:250	NULL
dilution	NULL
,	NULL
and	NULL
this	NULL
recognizes	NULL
some	NULL
of	NULL
the	NULL
many	NULL
isoforms	NULL
of	NULL
PML	NULL
expressed	NULL
.	NULL

The	NULL
RARa	NULL
antibody	NULL
,	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
Pierre	NULL
Cham-bon	NULL
,	NULL
recognizes	NULL
both	NULL
the	NULL
wild-type	NULL
RARa	NULL
and	NULL
the	NULL
PML/RARa	NULL
fusion	NULL
proteins	NULL
,	NULL
and	NULL
was	NULL
used	NULL
at	NULL
a	NULL
1:4,000	NULL
dilution	NULL
.	NULL

Blots	NULL
were	NULL
stained	NULL
with	NULL
Ponceau-	NULL
$	NULL
(	NULL
Sigma	NULL
)	NULL
to	NULL
assess	NULL
for	NULL
equal	NULL
protein	NULL
loading	NULL
.	NULL

Reverse	NULL
transcription	NULL
,	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
,	NULL
and	NULL
competitive	NULL
PCR	NULL
.	NULL

-	NULL
Reverse	NULL
transcription	NULL
(	NULL
RT	NULL
)	NULL
,	NULL
PCR	NULL
,	NULL
and	NULL
competitive	NULL
PCR	NULL
for	NULL
the	NULL
quantitation	NULL
of	NULL
PML/RARa	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
elsewhere	NULL
.	NULL
``	NULL

RA-resistant	NULL
and	NULL
-sensitive	NULL
NB4	NULL
cell	NULL
lines	NULL
.	NULL

-	NULL
NB4	NULL
cells	NULL
,	NULL
a	NULL
human	NULL
APL	NULL
cell	NULL
line	NULL
bearing	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
,	NULL
were	NULL
a	NULL
gift	NULL
of	NULL
Dr	NULL
M.	NULL
Lanotte	NULL
(	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
.	NULL
``	NULL

These	NULL
NB4	NULL
cells	NULL
were	NULL
subcloned	NULL
.	NULL

Of	NULL
20	NULL
subclones	NULL
isolated	NULL
and	NULL
analyzed	NULL
,	NULL
19	NULL
were	NULL
RA-sensitive	NULL
(	NULL
ie	NULL
,	NULL
they	NULL
growth	NULL
arrest	NULL
and	NULL
terminally	NULL
differentiate	NULL
in	NULL
10°	NULL
mol/L	NULL
RA	NULL
)	NULL
and	NULL
one	NULL
was	NULL
resistant	NULL
.	NULL

One	NULL
of	NULL
these	NULL
sensitive	NULL
clones	NULL
,	NULL
designated	NULL
NB4-S1	NULL
,	NULL
was	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
.	NULL

The	NULL
RA-resistant	NULL
clone	NULL
,	NULL
designated	NULL
NB4-R	NULL
1	NULL
,	NULL
can	NULL
be	NULL
continuously	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
``	NULL
mol/L	NULL
RA	NULL
.	NULL

Antiproliferative	NULL
and	NULL
cytotoxicity	NULL
assays	NULL
.	NULL

-	NULL
NB4	NULL
cells	NULL
were	NULL
seeded	NULL
in	NULL
6-well	NULL
clusters	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10°	NULL
cells/mL	NULL
and	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
culture	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
,	NULL
supplemented	NULL
with	NULL
100	NULL
U/mL	NULL
penicillin	NULL
,	NULL
100	NULL
mg/mL	NULL
streptomycin	NULL
,	NULL
and	NULL
20	NULL
mmol/	NULL
L	NULL
glutamine	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
at	NULL
37°C	NULL
in	NULL
humidified	NULL
air	NULL
.	NULL

The	NULL
antiproliferative	NULL
and	NULL
cytotoxic	NULL
effects	NULL
of	NULL
the	NULL
indicated	NULL
interferons	NULL
,	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
RA	NULL
,	NULL
were	NULL
determined	NULL
at	NULL
days	NULL
1	NULL
to	NULL
6	NULL
after	NULL
treatment	NULL
began	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
RA	NULL
,	NULL
maximal	NULL
differentiation	NULL
of	NULL
NB4	NULL
was	NULL
observed	NULL
after	NULL
4	NULL
to	NULL
5	NULL
days	NULL
of	NULL
culture	NULL
.	NULL

Viability	NULL
was	NULL
assessed	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

Interferons	NULL
«	NULL
,	NULL
3	NULL
,	NULL
and	NULL
y	NULL
were	NULL
directly	NULL
dissolved	NULL
in	NULL
RPMI	NULL
1640	NULL
,	NULL
whereas	NULL
RA	NULL
(	NULL
10	NULL
%	NULL
mol/L	NULL
stock	NULL
in	NULL
dimethyl	NULL
sulfoxide	NULL
[	NULL
DMSO	NULL
]	NULL
)	NULL
was	NULL
diluted	NULL
in	NULL
culture	NULL
medium	NULL
just	NULL
before	NULL
use	NULL
.	NULL

Nitroblue	NULL
Tetrazolium	NULL
reduction	NULL
assay	NULL
.	NULL

For	NULL
each	NULL
cell	NULL
sample	NULL
,	NULL
200	NULL
mg	NULL
Nitroblue	NULL
Tetrazolium	NULL
(	NULL
NBT	NULL
;	NULL
Sigma	NULL
Chemicals	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
solution	NULL
was	NULL
added	NULL
to	NULL
a	NULL
duplicate	NULL
set	NULL
of	NULL
siliconized	NULL
Eppendorf	NULL
tubes	NULL
and	NULL
10°cells/0.5	NULL
mL	NULL
medium	NULL
was	NULL
added	NULL
to	NULL
each	NULL
of	NULL
these	NULL
tubes	NULL
.	NULL

To	NULL
one	NULL
of	NULL
the	NULL
duplicate	NULL
tubes	NULL
,	NULL
100	NULL
ng	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
;	NULL
Sigma	NULL
)	NULL
was	NULL
added	NULL
.	NULL

Samples	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
10	NULL
minutes	NULL
,	NULL
then	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
15	NULL
minutes	NULL
.	NULL

Approximately	NULL
0.1	NULL
mL	NULL
of	NULL
cells	NULL
from	NULL
each	NULL
tube	NULL
was	NULL
cytospun	NULL
at	NULL
200	NULL
rpm	NULL
for	NULL
2	NULL
minutes	NULL
,	NULL
fixed	NULL
in	NULL
methanol	NULL
,	NULL
and	NULL
stained	NULL
with	NULL
Safranin-O	NULL
(	NULL
Fisher	NULL
Scientific	NULL
,	NULL
Pittsburgh	NULL
,	NULL
PA	NULL
)	NULL
.	NULL

A	NULL
minimum	NULL
of	NULL
100	NULL
cells	NULL
were	NULL
scored	NULL
microscopically	NULL
as	NULL
NBT	NULL
-negative	NULL
or	NULL
NBT-positive	NULL
(	NULL
blue	NULL
)	NULL
.	NULL

MTT	NULL
(	NULL
3-	NULL
[	NULL
4,5-dimethylthiazol-2-yl\-2,5-diphenyltetrazolium	NULL
bro-mide	NULL
;	NULL
Thiazolyl	NULL
blue	NULL
)	NULL
proliferation	NULL
assay	NULL
.	NULL

-	NULL
The	NULL
following	NULL
modification	NULL
of	NULL
Denizot	NULL
and	NULL
Lang	NULL
``	NULL
was	NULL
used	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
in	NULL
medium	NULL
without	NULL
phenol	NULL
red	NULL
.	NULL
``	NULL

''	NULL
For	NULL
each	NULL
sample	NULL
,	NULL
6	NULL
X	NULL
10'cells/6	NULL
mL	NULL
were	NULL
plated	NULL
,	NULL
in	NULL
duplicate	NULL
,	NULL
in	NULL
6-well	NULL
tissue	NULL
culture	NULL
plates	NULL
(	NULL
day	NULL
0	NULL
)	NULL
.	NULL

Twenty-four	NULL
hours	NULL
later	NULL
,	NULL
10°	NULL
mol/L	NULL
RA	NULL
(	NULL
Sigma	NULL
)	NULL
was	NULL
added	NULL
to	NULL
one	NULL
of	NULL
the	NULL
wells	NULL
,	NULL
and	NULL
the	NULL
vehicle	NULL
,	NULL
DMSO	NULL
,	NULL
diluted	NULL
1:10	NULL
``	NULL
,	NULL
was	NULL
added	NULL
to	NULL
the	NULL
duplicate	NULL
well	NULL
for	NULL
each	NULL
of	NULL
the	NULL
samples	NULL
(	NULL
day	NULL
1	NULL
)	NULL
.	NULL

On	NULL
day	NULL
3	NULL
,	NULL
cells	NULL
were	NULL
split	NULL
1:2	NULL
into	NULL
the	NULL
appropriate	NULL
medium	NULL
,	NULL
with	NULL
or	NULL
without	NULL
RA	NULL
,	NULL
and	NULL
this	NULL
was	NULL
the	NULL
first	NULL
day	NULL
of	NULL
the	NULL
MTT	NULL
assay	NULL
.	NULL

Fifty	NULL
milligrams	NULL
of	NULL
MTT	NULL
were	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3928	NULL
added	NULL
in	NULL
a	NULL
10	NULL
mL	NULL
volume	NULL
to	NULL
individual	NULL
wells	NULL
in	NULL
96-well	NULL
plates	NULL
.	NULL

Cells	NULL
were	NULL
resuspended	NULL
thoroughly	NULL
and	NULL
100	NULL
mL	NULL
of	NULL
cell	NULL
suspension	NULL
was	NULL
transferred	NULL
,	NULL
in	NULL
triplicate	NULL
,	NULL
to	NULL
the	NULL
wells	NULL
that	NULL
contained	NULL
the	NULL
MTT	NULL
.	NULL

Plates	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
,	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
,	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
,	NULL
for	NULL
4	NULL
hours	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
incubation	NULL
,	NULL
100	NULL
mL	NULL
of	NULL
0.04N	NULL
HCI	NULL
in	NULL
2-propanol	NULL
was	NULL
mixed	NULL
thoroughly	NULL
into	NULL
each	NULL
well	NULL
.	NULL

Absorption	NULL
at	NULL
570	NULL
nm	NULL
with	NULL
a	NULL
reading	NULL
at	NULL
650	NULL
nm	NULL
subtracted	NULL
for	NULL
background	NULL
was	NULL
measured	NULL
on	NULL
an	NULL
automated	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
reader	NULL
(	NULL
Emax-Reader	NULL
;	NULL
Molecular	NULL
Devices	NULL
,	NULL
Menlo	NULL
Park	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Triplicate	NULL
readings	NULL
for	NULL
each	NULL
sample	NULL
were	NULL
averaged	NULL
.	NULL

Cells	NULL
were	NULL
assessed	NULL
each	NULL
day	NULL
for	NULL
viability	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

Immunophenotypic	NULL
analysis	NULL
.	NULL

Cells	NULL
were	NULL
resuspended	NULL
at	NULL
10	NULL
'	NULL
cells/mL	NULL
in	NULL
PBS	NULL
containing	NULL
1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
BSA	NULL
)	NULL
.	NULL

For	NULL
each	NULL
sample	NULL
,	NULL
10°	NULL
cells	NULL
(	NULL
100	NULL
uL	NULL
)	NULL
were	NULL
added	NULL
to	NULL
each	NULL
of	NULL
two	NULL
tubes	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
at	NULL
4°C	NULL
for	NULL
1	NULL
hour	NULL
in	NULL
saturating	NULL
concentrations	NULL
of	NULL
either	NULL
FITC-labeled	NULL
murine	NULL
immunoglobulin	NULL
M	NULL
(	NULL
IgM	NULL
)	NULL
antibody	NULL
(	NULL
isotypic	NULL
control	NULL
)	NULL
or	NULL
the	NULL
FITC-labeled	NULL
mouse-antihuman	NULL
MoAb	NULL
,	NULL
Mol	NULL
(	NULL
Coulter	NULL
Immunology	NULL
,	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
PBS/1	NULL
%	NULL
BSA	NULL
and	NULL
resuspended	NULL
in	NULL
500	NULL
uL	NULL
0.5	NULL
%	NULL
paraformaldehyde	NULL
.	NULL

Cell	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
Becton	NULL
Dickinson	NULL
FACS	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Franklin	NULL
Lane	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Measurements	NULL
contained	NULL
a	NULL
minimum	NULL
of	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
.	NULL

RESULTS	NULL
PML	NULL
and	NULL
PML/RARa	NULL
expression	NULL
is	NULL
regulated	NULL
by	NULL
interferon	NULL
in	NULL
normal	NULL
circulating	NULL
monocytic	NULL
,	NULL
lymphocytic	NULL
,	NULL
and	NULL
polymorphonuclear	NULL
cells	NULL
;	NULL
in	NULL
APL	NULL
blasts	NULL
;	NULL
and	NULL
in	NULL
the	NULL
NB4	NULL
APL	NULL
cell	NULL
line	NULL
.	NULL

-	NULL
The	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
PML	NULL
gene	NULL
in	NULL
normal	NULL
circulating	NULL
neutrophils	NULL
and	NULL
monocytes	NULL
was	NULL
analyzed	NULL
by	NULL
Northern	NULL
analysis	NULL
performed	NULL
on	NULL
total	NULL
RNA	NULL
isolated	NULL
from	NULL
cells	NULL
from	NULL
healthy	NULL
human	NULL
donors	NULL
(	NULL
see	NULL
Methods	NULL
)	NULL
.	NULL

PMNs	NULL
and	NULL
monocytes	NULL
were	NULL
also	NULL
treated	NULL
,	NULL
before	NULL
RNA	NULL
extraction	NULL
,	NULL
with	NULL
E	NULL
coli	NULL
LPS	NULL
,	NULL
TNF	NULL
,	NULL
or	NULL
interferon	NULL
y	NULL
(	NULL
see	NULL
the	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

PML	NULL
expression	NULL
was	NULL
difficult	NULL
to	NULL
detect	NULL
in	NULL
untreated	NULL
PMNs	NULL
and	NULL
monocytes	NULL
even	NULL
after	NULL
long	NULL
exposures	NULL
(	NULL
up	NULL
to	NULL
2	NULL
weeks	NULL
of	NULL
autoradiography	NULL
;	NULL
Fig	NULL
1A	NULL
)	NULL
.	NULL

While	NULL
interferon	NULL
y	NULL
markedly	NULL
augmented	NULL
PML	NULL
expression	NULL
,	NULL
especially	NULL
in	NULL
PMNs	NULL
,	NULL
neither	NULL
TNF	NULL
nor	NULL
LPS	NULL
had	NULL
observed	NULL
effects	NULL
on	NULL
PML	NULL
expression	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
.	NULL

Despite	NULL
a	NULL
higher	NULL
level	NULL
of	NULL
expression	NULL
in	NULL
APL	NULL
cells	NULL
and	NULL
myeloid	NULL
precursors	NULL
,	NULL
PML	NULL
was	NULL
expressed	NULL
at	NULL
low	NULL
levels	NULL
in	NULL
mature	NULL
circulating	NULL
myeloid	NULL
cells	NULL
and	NULL
was	NULL
specifically	NULL
regulated	NULL
by	NULL
interferon	NULL
.	NULL

LPS	NULL
,	NULL
which	NULL
activates	NULL
circulating	NULL
leukocytes	NULL
,	NULL
does	NULL
not	NULL
regulate	NULL
PML	NULL
.	NULL

It	NULL
is	NULL
notable	NULL
that	NULL
the	NULL
Northern	NULL
analysis	NULL
expression	NULL
pattern	NULL
following	NULL
interferon	NULL
y	NULL
treatment	NULL
of	NULL
PMNs	NULL
is	NULL
different	NULL
from	NULL
that	NULL
found	NULL
for	NULL
PML	NULL
in	NULL
other	NULL
tissues	NULL
.	NULL

The	NULL
lower	NULL
of	NULL
the	NULL
three	NULL
major	NULL
bands	NULL
usually	NULL
recognized	NULL
by	NULL
the	NULL
cDNA	NULL
probe	NULL
used	NULL
(	NULL
LAV	NULL
10	NULL
,	NULL
see	NULL
Methods	NULL
)	NULL
is	NULL
barely	NULL
detected	NULL
,	NULL
while	NULL
the	NULL
three	NULL
bands	NULL
are	NULL
detected	NULL
in	NULL
the	NULL
monocyte	NULL
samples	NULL
treated	NULL
with	NULL
interferon	NULL
y	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
indicates	NULL
differences	NULL
in	NULL
PML	NULL
isoform	NULL
expression	NULL
in	NULL
NASON-BURCHENAL	NULL
ET	NULL
AL	NULL
normal	NULL
circulating	NULL
neutrophils	NULL
with	NULL
reduced	NULL
or	NULL
absent	NULL
expression	NULL
of	NULL
PML	NULL
isoform	NULL
3	NULL
.	NULL

``	NULL
°	NULL
PML	NULL
protein	NULL
expression	NULL
was	NULL
also	NULL
studied	NULL
by	NULL
immunofluorescence	NULL
analysis	NULL
in	NULL
polymorphonucleate	NULL
(	NULL
PMN	NULL
)	NULL
,	NULL
lymphocytic	NULL
(	NULL
LP	NULL
)	NULL
,	NULL
and	NULL
monocytic	NULL
(	NULL
MON	NULL
)	NULL
blood	NULL
cells	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
the	NULL
MoAb	NULL
PG-M3	NULL
,	NULL
as	NULL
described	NULL
earlier	NULL
.	NULL

PML	NULL
protein	NULL
was	NULL
undetectable	NULL
before	NULL
interferon	NULL
y	NULL
treatment	NULL
in	NULL
all	NULL
three	NULL
populations	NULL
.	NULL

The	NULL
simultaneous	NULL
staining	NULL
with	NULL
DAPI	NULL
confirmed	NULL
the	NULL
presence	NULL
of	NULL
cells	NULL
and	NULL
displayed	NULL
the	NULL
nuclear	NULL
structure	NULL
.	NULL

Treatment	NULL
with	NULL
interferon	NULL
y	NULL
induced	NULL
a	NULL
typical	NULL
speckle-like	NULL
staining	NULL
in	NULL
the	NULL
nucleus	NULL
of	NULL
PMN	NULL
cells	NULL
.	NULL

Both	NULL
a	NULL
speckle-like	NULL
and	NULL
a	NULL
diffuse	NULL
nuclear	NULL
staining	NULL
were	NULL
present	NULL
in	NULL
lymphocytic	NULL
cells	NULL
after	NULL
interferon	NULL
y	NULL
treatment	NULL
.	NULL

Monocytes	NULL
displayed	NULL
a	NULL
speckled	NULL
nuclear	NULL
distribution	NULL
,	NULL
with	NULL
some	NULL
cells	NULL
having	NULL
a	NULL
cytoplasmic	NULL
staining	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

These	NULL
data	NULL
confirm	NULL
the	NULL
low	NULL
basal	NULL
level	NULL
of	NULL
PML	NULL
expression	NULL
in	NULL
mature	NULL
circulating	NULL
PMNs	NULL
,	NULL
lymphocytes	NULL
,	NULL
and	NULL
monocytes	NULL
and	NULL
show	NULL
that	NULL
PML	NULL
expression	NULL
is	NULL
markedly	NULL
increased	NULL
by	NULL
interferon	NULL
y	NULL
treatment	NULL
.	NULL

PML	NULL
and	NULL
PML/RARa	NULL
expression	NULL
was	NULL
also	NULL
monitored	NULL
by	NULL
RT-quantitative	NULL
PCR	NULL
in	NULL
blasts	NULL
derived	NULL
from	NULL
APL	NULL
patients	NULL
upon	NULL
exposure	NULL
to	NULL
interferon	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL
``	NULL

In	NULL
both	NULL
cases	NULL
,	NULL
PML/	NULL
RARa	NULL
mRNA	NULL
was	NULL
augmented	NULL
by	NULL
interferon	NULL
in	NULL
parallel	NULL
with	NULL
PML	NULL
transcripts	NULL
,	NULL
suggesting	NULL
the	NULL
portion	NULL
of	NULL
PML	NULL
fused	NULL
to	NULL
RARa	NULL
retains	NULL
the	NULL
element	NULL
(	NULL
s	NULL
)	NULL
that	NULL
mediate	NULL
interferon	NULL
induc-ibility	NULL
.	NULL

The	NULL
differentiation	NULL
at	NULL
24	NULL
hours	NULL
,	NULL
as	NULL
estimated	NULL
by	NULL
NBT	NULL
and	NULL
Mo-1	NULL
analyses	NULL
,	NULL
was	NULL
negligible	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
PML	NULL
and	NULL
PML/RARa	NULL
was	NULL
regulated	NULL
by	NULL
interferon	NULL
in	NULL
mature	NULL
circulating	NULL
myeloid	NULL
cells	NULL
prompted	NULL
us	NULL
to	NULL
confirm	NULL
these	NULL
data	NULL
with	NULL
Western	NULL
analysis	NULL
.	NULL

For	NULL
this	NULL
pur-pose	NULL
,	NULL
NB4-S1	NULL
and	NULL
NB4-R	NULL
1	NULL
cells	NULL
were	NULL
exposed	NULL
for	NULL
36	NULL
hours	NULL
to	NULL
100	NULL
U/mL	NULL
and	NULL
1,000	NULL
U/mL	NULL
of	NULL
interferons	NULL
a	NULL
,	NULL
8	NULL
,	NULL
and	NULL
y.	NULL
PML	NULL
,	NULL
RARa	NULL
,	NULL
and	NULL
PML/RARa	NULL
protein	NULL
expression	NULL
was	NULL
monitored	NULL
by	NULL
Western	NULL
analysis	NULL
(	NULL
Fig	NULL
2	NULL
and	NULL
the	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

In	NULL
NB4-S1	NULL
cells	NULL
(	NULL
Fig	NULL
2A	NULL
)	NULL
,	NULL
PML/RARa	NULL
,	NULL
and	NULL
PML	NULL
protein	NULL
levels	NULL
were	NULL
upregulated	NULL
after	NULL
interferon	NULL
treatment	NULL
.	NULL

The	NULL
upper	NULL
band	NULL
in	NULL
the	NULL
top	NULL
panel	NULL
represents	NULL
PML/RARa	NULL
,	NULL
as	NULL
seen	NULL
with	NULL
the	NULL
RARa	NULL
antibody	NULL
,	NULL
and	NULL
,	NULL
excepting	NULL
the	NULL
100	NULL
U/mL	NULL
interferon	NULL
a	NULL
treatment	NULL
group	NULL
,	NULL
there	NULL
is	NULL
a	NULL
twofold	NULL
increase	NULL
in	NULL
expression	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
densitometric	NULL
scanning	NULL
.	NULL

Hybridiza-tion	NULL
with	NULL
the	NULL
PML	NULL
antibody	NULL
shows	NULL
a	NULL
twofold	NULL
to	NULL
threefold	NULL
increase	NULL
in	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
PML	NULL
protein	NULL
.	NULL

Likewise	NULL
,	NULL
100	NULL
U/mL	NULL
interferon	NULL
a	NULL
treatment	NULL
shows	NULL
no	NULL
increase	NULL
in	NULL
PML	NULL
protein	NULL
levels	NULL
.	NULL

In	NULL
NB4-R	NULL
1	NULL
cells	NULL
(	NULL
Fig	NULL
2B	NULL
)	NULL
,	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
PML/RARa	NULL
is	NULL
increased	NULL
twofold	NULL
in	NULL
all	NULL
treatment	NULL
groups	NULL
.	NULL

Notably	NULL
,	NULL
although	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
PML	NULL
protein	NULL
did	NULL
not	NULL
change	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
there	NULL
is	NULL
differential	NULL
regulation	NULL
of	NULL
the	NULL
PML	NULL
isoforms	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
of	NULL
bands	NULL
is	NULL
also	NULL
seen	NULL
in	NULL
U937	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
while	NULL
HL-60	NULL
cells	NULL
present	NULL
Fig	NULL
1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
PML	NULL
mRNA	NULL
expression	NULL
in	NULL
activated	NULL
human	NULL
monocytes	NULL
and	NULL
polymorphonuciear	NULL
cells	NULL
(	NULL
PMN	NULL
)	NULL
}	NULL
before	NULL
and	NULL
after	NULL
stimulation	NULL
with	NULL
LPS	NULL
,	NULL
TNF	NULL
,	NULL
interferon	NULL
(	NULL
IFN	NULL
}	NULL
y	NULL
,	NULL
or	NULL
without	NULL
treatment	NULL
(	NULL
¢	NULL
)	NULL
.	NULL

A	NULL
total	NULL
of	NULL
7	NULL
mg	NULL
of	NULL
total	NULL
cellular	NULL
RNA	NULL
was	NULL
loaded	NULL
in	NULL
each	NULL
lane	NULL
.	NULL

The	NULL
bands	NULL
that	NULL
characterize	NULL
the	NULL
4	NULL
major	NULL
PML	NULL
isoforms	NULL
are	NULL
present	NULL
in	NULL
the	NULL
IFNy-	NULL
treated	NULL
monocytes	NULL
lane	NULL
(	NULL
black	NULL
arrowhead	NULL
indicates	NULL
the	NULL
2.1-kb	NULL
transcript	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
trancript	NULL
encoding	NULL
for	NULL
PML	NULL
isoform	NULL
3	NULL
is	NULL
not	NULL
visible	NULL
in	NULL
IFN+y-stimulated	NULL
PMN	NULL
lanes	NULL
as	NULL
indicated	NULL
by	NULL
the	NULL
empty	NULL
arrowhead	NULL
.	NULL

The	NULL
quantity	NULL
of	NULL
loaded	NULL
mRNA	NULL
was	NULL
normalized	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
G-actin	NULL
mRNA	NULL
signal	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Immunofiuorescence	NULL
analysis	NULL
of	NULL
polymorphonucleates	NULL
(	NULL
PMN	NULL
)	NULL
,	NULL
lymphocytes	NULL
{	NULL
LP	NULL
}	NULL
,	NULL
and	NULL
monocytes	NULL
(	NULL
MON	NULL
)	NULL
stained	NULL
with	NULL
MoAb	NULL
PML-PG3	NULL
shows	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
protein	NULL
before	NULL
IFNy	NULL
treatment	NULL
.	NULL

Treatment	NULL
with	NULL
IFNy	NULL
leads	NULL
to	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
typical	NULL
speckle-like	NULL
staining	NULL
in	NULL
the	NULL
nucleus	NULL
of	NULL
PMN	NULL
ceils	NULL
.	NULL

A	NULL
speckle	NULL
and	NULL
a	NULL
diffuse	NULL
nuclear	NULL
staining	NULL
is	NULL
also	NULL
present	NULL
in	NULL
LPs	NULL
.	NULL

A	NULL
speckled	NULL
nuclear	NULL
distribution	NULL
is	NULL
visible	NULL
in	NULL
monocytes	NULL
,	NULL
but	NULL
in	NULL
some	NULL
cells	NULL
cytoplasmic	NULL
staining	NULL
is	NULL
detected	NULL
.	NULL

The	NULL
nuclear	NULL
cellular	NULL
staining	NULL
with	NULL
DAPI	NULL
of	NULL
each	NULL
field	NULL
is	NULL
also	NULL
shown	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IFN	NULL
AND	NULL
RA-RESISTANCE	NULL
IN	NULL
APL	NULL
3929	NULL
Monocytes	NULL
PMN	NULL
>	NULL
bg	NULL
&	NULL
5	NULL
A	NULL
#	NULL
.	NULL

Z	NULL
.	NULL

#	NULL
.	NULL

A	NULL
Ba	NULL
#	NULL
.	NULL

Z.	NULL
A4	NULL
-100	NULL
R4	NULL
o	NULL
=-4	NULL
A	NULL
&	NULL
4	NULL
o	NULL
PML	NULL
B-actin	NULL
PMN	NULL
MoN	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3930	NULL
Table	NULL
1	NULL
.	NULL

Quantification	NULL
of	NULL
PML-RARa	NULL
Transcripts	NULL
in	NULL
APL	NULL
Cells	NULL
Sample	NULL
No	NULL
.	NULL

to	NULL
tray	NULL
twa	NULL
1	NULL
BM	NULL
66	NULL
425	NULL
500	NULL
2	NULL
PB	NULL
220	NULL
590	NULL
8,500	NULL
3	NULL
BM	NULL
210	NULL
580	NULL
1,100	NULL
4	NULL
PB	NULL
4,100	NULL
6,500	NULL
5,800	NULL
Cells	NULL
were	NULL
exposed	NULL
to	NULL
100	NULL
U/mL~	NULL
'	NULL
a	NULL
(	NULL
ta	NULL
)	NULL
and	NULL
y	NULL
(	NULL
t	NULL
»	NULL
:	NULL
y	NULL
)	NULL
interferon	NULL
;	NULL
(	NULL
t	NULL
,	NULL
)	NULL
represents	NULL
the	NULL
baseline	NULL
control	NULL
.	NULL

Numbers	NULL
are	NULL
of	NULL
PML-RARa	NULL
molecules	NULL
per	NULL
microgram	NULL
RNA	NULL
(	NULL
x	NULL
10°	NULL
)	NULL
.	NULL

Abbreviations	NULL
:	NULL
BM	NULL
,	NULL
bone	NULL
marrow	NULL
;	NULL
PB	NULL
,	NULL
peripheral	NULL
blood	NULL
.	NULL

a	NULL
slightly	NULL
different	NULL
PML	NULL
expression	NULL
pattern	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
which	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
seen	NULL
by	NULL
Chelbi-Alix	NULL
et	NULL
al	NULL
.	NULL
``	NULL

Another	NULL
PML	NULL
antibody	NULL
,	NULL
PML-3	NULL
(	NULL
courtesy	NULL
of	NULL
Dr	NULL
P.G	NULL
.	NULL

Pelicci	NULL
)	NULL
,	NULL
which	NULL
recognizes	NULL
a	NULL
subset	NULL
of	NULL
PML	NULL
isoforms	NULL
,	NULL
shows	NULL
a	NULL
pattern	NULL
of	NULL
bands	NULL
consistent	NULL
with	NULL
that	NULL
seen	NULL
with	NULL
PG-M3	NULL
in	NULL
the	NULL
aforementioned	NULL
cell	NULL
lines	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
bands	NULL
are	NULL
expected	NULL
to	NULL
be	NULL
some	NULL
of	NULL
the	NULL
many	NULL
isoforms	NULL
of	NULL
PML	NULL
that	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
exist	NULL
due	NULL
to	NULL
differential	NULL
splicing	NULL
.	NULL
``	NULL

Some	NULL
molecular	NULL
weights	NULL
correspond	NULL
to	NULL
the	NULL
expected	NULL
size	NULL
,	NULL
while	NULL
others	NULL
that	NULL
do	NULL
not	NULL
are	NULL
most	NULL
likely	NULL
isoforms	NULL
altered	NULL
by	NULL
posttranslational	NULL
modification	NULL
.	NULL

It	NULL
has	NULL
been	NULL
previously	NULL
shown	NULL
that	NULL
a	NULL
transfected	NULL
isoform	NULL
of	NULL
PML	NULL
(	NULL
PML3	NULL
:	NULL
exon	NULL
3-4-6-7	NULL
)	NULL
with	NULL
a	NULL
predicted	NULL
molecular	NULL
weight	NULL
of	NULL
approximately	NULL
65	NULL
Kd	NULL
migrated	NULL
at	NULL
approximately	NULL
97	NULL
Kd	NULL
.	NULL
``	NULL

''	NULL
Similar	NULL
patterns	NULL
of	NULL
multiple	NULL
PML	NULL
isoforms	NULL
have	NULL
been	NULL
seen	NULL
in	NULL
Western	NULL
analysis	NULL
of	NULL
other	NULL
cells	NULL
(	NULL
HL-	NULL
A	NULL
NB4-S1	NULL
IFN-	NULL
IFN-B	NULL
IFN-y	NULL
U	NULL
100	NULL
1000	NULL
100	NULL
1000	NULL
100	NULL
1000	NULL
PML/RARo	NULL
,	NULL
.	NULL

mee	NULL
cme	NULL
cmt	NULL
dnb	NULL
dge	NULL
diet	NULL
_	NULL
97	NULL
Kd	NULL
-	NULL
66	NULL
RARa	NULL
nore	NULL
®	NULL
=	NULL
-46	NULL
RAR	NULL
«	NULL
Ab	NULL
lite	NULL
c	NULL
dle	NULL
Jase	NULL
wats	NULL
«	NULL
cee	NULL
Cat	NULL
_	NULL
__	NULL
Pm-nuﬂﬁhiw	NULL
Slam-ﬂ—	NULL
8	NULL
«	NULL
.	NULL

?	NULL

“	NULL
-	NULL
t	NULL
#	NULL
wigan	NULL
..	NULL
m	NULL
C	NULL
&	NULL
#	NULL
``	NULL
«	NULL
ken	NULL
.	NULL

sam	NULL
``	NULL
———30	NULL
PML	NULL
Ab	NULL
NASON-BURCHENAL	NULL
ET	NULL
AL	NULL
60	NULL
and	NULL
HeLa	NULL
cells	NULL
``	NULL
;	NULL
PA317	NULL
cells	NULL
``	NULL
;	NULL
HL-60	NULL
and	NULL
U937	NULL
,	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Enhancement	NULL
of	NULL
the	NULL
antiproliferative	NULL
and	NULL
cytotoxic	NULL
effects	NULL
of	NULL
interferon	NULL
and	NULL
RA	NULL
on	NULL
NB4	NULL
cells	NULL
.	NULL

The	NULL
antiproliferative	NULL
and	NULL
cytotoxic	NULL
effects	NULL
of	NULL
class	NULL
I	NULL
and	NULL
II	NULL
interferons	NULL
(	NULL
interferons	NULL
a	NULL
.	NULL

B	NULL
,	NULL
and	NULL
y	NULL
)	NULL
on	NULL
NB4	NULL
cells	NULL
were	NULL
compared	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
10°	NULL
mol/L	NULL
RA	NULL
(	NULL
Fig	NULL
3	NULL
and	NULL
the	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

Three	NULL
different	NULL
concentrations	NULL
of	NULL
the	NULL
three	NULL
interferons	NULL
were	NULL
used	NULL
:	NULL
10	NULL
,	NULL
100	NULL
,	NULL
and	NULL
1,000	NULL
U/mL	NULL
.	NULL

The	NULL
antiproliferative	NULL
effect	NULL
of	NULL
RA	NULL
alone	NULL
or	NULL
at	NULL
concentrations	NULL
ranging	NULL
from	NULL
10	NULL
~	NULL
to	NULL
10	NULL
~*	NULL
mol/L	NULL
was	NULL
independently	NULL
assessed	NULL
.	NULL

RA	NULL
was	NULL
cytotoxic	NULL
at	NULL
10	NULL
~*	NULL
mol/L	NULL
.	NULL

RA	NULL
alone	NULL
exerted	NULL
an	NULL
antiproliferative	NULL
effect	NULL
at	NULL
a	NULL
concentration	NULL
10	NULL
~	NULL
``	NULL
mol/L	NULL
,	NULL
with	NULL
maximal	NULL
inhibition	NULL
at	NULL
mol/L	NULL
(	NULL
80	NULL
%	NULL
)	NULL
,	NULL
which	NULL
became	NULL
evident	NULL
on	NULL
the	NULL
second	NULL
day	NULL
of	NULL
culture	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

NB4	NULL
cells	NULL
'	NULL
doubling	NULL
time	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
RA	NULL
or	NULL
at	NULL
10~	NULL
'	NULL
mol/L	NULL
,	NULL
was	NULL
approximately	NULL
44	NULL
hours	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

At	NULL
concentrations	NULL
of	NULL
10	NULL
U/mL	NULL
,	NULL
these	NULL
interferons	NULL
did	NULL
not	NULL
exert	NULL
any	NULL
observed	NULL
antiproliferative	NULL
effects	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
RA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

At	NULL
doses	NULL
achievable	NULL
in	NULL
vivo	NULL
(	NULL
100	NULL
U/mL	NULL
)	NULL
,	NULL
these	NULL
interferons	NULL
inhibited	NULL
cell	NULL
growth	NULL
in	NULL
a	NULL
similar	NULL
manner	NULL
,	NULL
with	NULL
maximal	NULL
inhibition	NULL
of	NULL
30	NULL
%	NULL
to	NULL
40	NULL
%	NULL
reached	NULL
at	NULL
day	NULL
4	NULL
(	NULL
Fig	NULL
3A	NULL
)	NULL
.	NULL

If	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
interferon	NULL
and	NULL
RA	NULL
,	NULL
an	NULL
enhanced	NULL
antiproliferative	NULL
effect	NULL
was	NULL
obtained	NULL
(	NULL
Fig	NULL
3A	NULL
)	NULL
.	NULL

Even	NULL
more	NULL
marked	NULL
proliferative	NULL
inhibition	NULL
occurred	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
a	NULL
higher	NULL
dose	NULL
of	NULL
interferon	NULL
(	NULL
1,000	NULL
U/mL	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
treatment	NULL
with	NULL
interfer-	NULL
B	NULL
NB4-R1	NULL
IFN-c	NULL
_	NULL
IFN-B	NULL
__	NULL
IFN-y	NULL
U	NULL
100	NULL
1000	NULL
100	NULL
1000	NULL
100	NULL
1000	NULL
ﬁ	NULL
‘	NULL
“	NULL
“	NULL
“	NULL
-97	NULL
-	NULL
66	NULL
Kd	NULL
$	NULL
Yp	NULL
-46	NULL
stin	NULL
«	NULL
4m	NULL
a+	NULL
RARc	NULL
KB	NULL
as	NULL
wo	NULL
¥2	NULL
RARa	NULL
Ab	NULL
usses	NULL
PML	NULL
-	NULL
wwe	NULL
wae	NULL
woe	NULL
sooe	NULL
wom	NULL
sp	NULL
cout	NULL
_-	NULL
4G	NULL
~6=	NULL
”	NULL
#	NULL
§Q_30	NULL
PML	NULL
Ab	NULL
Fig	NULL
2	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
IFN	NULL
treatment	NULL
of	NULL
NB4-S1	NULL
and	NULL
NB4-R1	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
for	NULL
36	NULL
hours	NULL
with	NULL
100	NULL
U/mL	NULL
or	NULL
1,000	NULL
U/mL	NULL
IFNa	NULL
,	NULL
,	NULL
or	NULL
y.	NULL
U	NULL
,	NULL
untreated	NULL
(	NULL
vehicle-treated	NULL
)	NULL
control	NULL
cells	NULL
.	NULL

The	NULL
molecular	NULL
weight	NULL
ladder	NULL
is	NULL
shown	NULL
.	NULL

(	NULL
A	NULL
)	NULL
NB4-S1	NULL
cell	NULL
protein	NULL
extracts	NULL
,	NULL
hybridized	NULL
with	NULL
either	NULL
the	NULL
RARa	NULL
antibody	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
or	NULL
the	NULL
PML	NULL
antibody	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
NB4-R1	NULL
cell	NULL
protein	NULL
extracts	NULL
,	NULL
hybridized	NULL
with	NULL
either	NULL
the	NULL
RARa	NULL
antibody	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
or	NULL
the	NULL
PML	NULL
antibody	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IFN	NULL
AND	NULL
RA-RESISTANCE	NULL
IN	NULL
APL	NULL
3931	NULL
a	NULL
IFN	NULL
100	NULL
WRA	NULL
1°	NULL
``	NULL
ﬂIFN	NULL
109	NULL
URA	NULL
a	NULL
80	NULL
ECO	NULL
g	NULL
so	NULL
a*	NULL
``	NULL
a	NULL
a	NULL
40	NULL
a	NULL
40	NULL
3	NULL
3	NULL
e	NULL
20	NULL
£29	NULL
0	NULL
0	NULL
g	NULL
400	NULL
20	NULL
B0	NULL
4	NULL
0	NULL
50	NULL
6	NULL
0	NULL
200830	NULL
0	NULL
400	NULL
50°06	NULL
time	NULL
(	NULL
days	NULL
)	NULL
time	NULL
(	NULL
days	NULL
)	NULL
B	NULL
y	NULL
IFN	NULL
100	NULL
WRA	NULL
a	NULL
IPN	NULL
100	NULL
URA	NULL
,	NULL
4	NULL
,	NULL
A	NULL
iew	NULL
100	NULL
wha	NULL
100	NULL
t	NULL
I	NULL
s	NULL
o	NULL
a	NULL
o	NULL
a	NULL
ot	NULL
-	NULL
#	NULL
l	NULL
$	NULL
E§	NULL
£	NULL
€	NULL
gut	NULL
£	NULL
eof	NULL
ECO	NULL
&	NULL
5	NULL
€	NULL
3	NULL
a	NULL
of	NULL
%	NULL
40	NULL
1+°	NULL
4	NULL
f	NULL
>	NULL
t	NULL
20	NULL
[	NULL
-	NULL
20	NULL
}	NULL
6	NULL
g	NULL
g	NULL
L__L__A_-_AL__A__A	NULL
__	NULL
ae	NULL
00	NULL
to	NULL
r	NULL
:	NULL
0	NULL
30	NULL
400	NULL
50s	NULL
e	NULL
0	NULL
1	NULL
B00	NULL
400	NULL
50008	NULL
po	NULL
4	NULL
o	NULL
20	NULL
30	NULL
400	NULL
500	NULL
%	NULL
lime	NULL
{	NULL
dave	NULL
}	NULL
time	NULL
(	NULL
days	NULL
)	NULL
time	NULL
(	NULL
days	NULL
)	NULL
1.s	NULL
NB4-81	NULL
1.s	NULL
NB4-R1	NULL
1.4	NULL
1.4	NULL
g	NULL
*	NULL
:	NULL
&	NULL
**	NULL
-o-	NULL
control	NULL
&	NULL
1	NULL
80	NULL
a	NULL
$	NULL
§	NULL
-	NULL
#	NULL
-	NULL
IFN	NULL
9.3	NULL
0.s	NULL
0.s	NULL
E	NULL
0.5	NULL
-O-	NULL
RA	NULL
g	NULL
§	NULL
o..	NULL
-e-	NULL
RA+	NULL
{	NULL
FN	NULL
0.2	NULL
0.2	NULL
0	NULL
°	NULL
0	NULL
4	NULL
6	NULL
3	NULL
4	NULL
3	NULL
6	NULL
time	NULL
(	NULL
days	NULL
)	NULL
time	NULL
(	NULL
days	NULL
)	NULL
Fig	NULL
3	NULL
.	NULL

-	NULL
Proliferation	NULL
and	NULL
viability	NULL
of	NULL
NB4	NULL
cells	NULL
after	NULL
treatment	NULL
with	NULL
class	NULL
|	NULL
and	NULL
Il	NULL
interferons	NULL
(	NULL
«	NULL
,	NULL
,	NULL
and	NULL
y	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
10°	NULL
mol/L	NULL
RA	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Antiproliferative	NULL
effects	NULL
of	NULL
100	NULL
U/ml	NULL
.	NULL

of	NULL
each	NULL
of	NULL
the	NULL
3	NULL
types	NULL
of	NULL
IFNs	NULL
,	NULL
of	NULL
the	NULL
RA	NULL
,	NULL
and	NULL
of	NULL
the	NULL
additive	NULL
effect	NULL
of	NULL
RA	NULL
+	NULL
IFNs	NULL
treatment	NULL
are	NULL
shown	NULL
as	NULL
cell	NULL
number	NULL
(	NULL
n.	NULL
cells	NULL
)	NULL
versus	NULL
time	NULL
in	NULL
days	NULL
.	NULL

Untreated	NULL
cells	NULL
are	NULL
used	NULL
as	NULL
a	NULL
control	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Cell	NULL
viability	NULL
is	NULL
affected	NULL
only	NULL
in	NULL
RA	NULL
+	NULL
IFN-treated	NULL
NBA4	NULL
ceils	NULL
.	NULL

(	NULL
C	NULL
)	NULL
MTT	NULL
assay	NULL
of	NULL
NB4-S1	NULL
and	NULL
NB4-R1	NULL
grown	NULL
in	NULL
RA	NULL
and	NULL
IFNy	NULL
.	NULL

The	NULL
X-axis	NULL
indicates	NULL
the	NULL
days	NULL
the	NULL
MTT	NULL
assay	NULL
was	NULL
performed	NULL
.	NULL

Reduction	NULL
of	NULL
MTT	NULL
to	NULL
blue	NULL
formazan	NULL
was	NULL
measured	NULL
spectrophotomatrically	NULL
,	NULL
and	NULL
the	NULL
Y-axis	NULL
represents	NULL
the	NULL
optical	NULL
density	NULL
.	NULL

ons	NULL
(	NULL
Fig	NULL
3B	NULL
)	NULL
,	NULL
and	NULL
at	NULL
all	NULL
the	NULL
concentrations	NULL
used	NULL
(	NULL
10~'°	NULL
to	NULL
10~	NULL
``	NULL
mol/L	NULL
)	NULL
,	NULL
RA	NULL
exerted	NULL
minimal	NULL
effects	NULL
on	NULL
NB4	NULL
cell	NULL
viability	NULL
(	NULL
Fig	NULL
3B	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Cytotoxicity	NULL
was	NULL
observed	NULL
when	NULL
NB4	NULL
celis	NULL
were	NULL
treated	NULL
simultaneously	NULL
with	NULL
interferon	NULL
and	NULL
RA	NULL
;	NULL
interferon	NULL
#	NULL
was	NULL
more	NULL
cytotoxic	NULL
than	NULL
a	NULL
or	NULL
y	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
.	NULL

These	NULL
interferons	NULL
markedly	NULL
inhibited	NULL
growth	NULL
,	NULL
and	NULL
this	NULL
effect	NULL
was	NULL
enhanced	NULL
by	NULL
RA	NULL
treatment	NULL
in	NULL
NB4	NULL
cells	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
.	NULL

Differentiating	NULL
effects	NULL
of	NULL
RA	NULL
and	NULL
interferon	NULL
y	NULL
on	NULL
NB4	NULL
cells	NULL
.	NULL

-	NULL
In	NULL
NB4	NULL
cells	NULL
,	NULL
the	NULL
differentiation-inducing	NULL
effects	NULL
of	NULL
interferon	NULL
a	NULL
,	NULL
3	NULL
,	NULL
and	NULL
y	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
presence	NULL
of	NULL
RA	NULL
(	NULL
10~°	NULL
mol/L	NULL
)	NULL
,	NULL
was	NULL
assessed	NULL
using	NULL
an	NULL
immunophenotypic	NULL
marker	NULL
and	NULL
the	NULL
NBT	NULL
assay	NULL
.	NULL

As	NULL
previously	NULL
reported	NULL
,	NULL
NB4	NULL
cells	NULL
,	NULL
when	NULL
treated	NULL
with	NULL
RA	NULL
,	NULL
mature	NULL
along	NULL
the	NULL
myeloid	NULL
path-way	NULL
,	NULL
characterized	NULL
by	NULL
expression	NULL
of	NULL
the	NULL
myelomonocytic	NULL
marker	NULL
Mo-1	NULL
.	NULL

**	NULL
'	NULL
When	NULL
treated	NULL
with	NULL
10~°	NULL
mol/L	NULL
RA	NULL
,	NULL
expres-	NULL
sion	NULL
of	NULL
the	NULL
immunophenotypic	NULL
marker	NULL
,	NULL
Mo-1	NULL
,	NULL
increased	NULL
substantially	NULL
in	NULL
NB4-~S1	NULL
cells	NULL
(	NULL
~83	NULL
%	NULL
;	NULL
Fig	NULL
4	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
this	NULL
pattern	NULL
,	NULL
NB4-R1	NULL
cells	NULL
have	NULL
a	NULL
minimal	NULL
shift	NULL
in	NULL
expression	NULL
(	NULL
~7	NULL
%	NULL
increase	NULL
)	NULL
.	NULL

When	NULL
treated	NULL
with	NULL
100	NULL
U/mL	NULL
.	NULL

interferon	NULL
y	NULL
alone	NULL
,	NULL
NB4-R1	NULL
cells	NULL
responded	NULL
to	NULL
a	NULL
slightly	NULL
higher	NULL
degree	NULL
than	NULL
NB4-S1	NULL
cells	NULL
(	NULL
~22	NULL
%	NULL
and	NULL
~16	NULL
%	NULL
shift	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

With	NULL
the	NULL
combination	NULL
of	NULL
100	NULL
U/mL	NULL
interferon	NULL
y	NULL
plus	NULL
RA	NULL
,	NULL
there	NULL
was	NULL
a	NULL
substantial	NULL
increase	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
Mo-1	NULL
in	NULL
the	NULL
NB4-R	NULL
1	NULL
cells	NULL
(	NULL
~32	NULL
%	NULL
from	NULL
baseline	NULL
)	NULL
.	NULL

This	NULL
result	NULL
indicates	NULL
an	NULL
additive	NULL
effect	NULL
of	NULL
the	NULL
two	NULL
compounds	NULL
.	NULL

This	NULL
combined	NULL
treatment	NULL
did	NULL
not	NULL
have	NULL
any	NULL
greater	NULL
maturation	NULL
effect	NULL
on	NULL
NB4-S1	NULL
cells	NULL
than	NULL
did	NULL
RA	NULL
alone	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
69	NULL
%	NULL
increase	NULL
from	NULL
baseline	NULL
is	NULL
less	NULL
than	NULL
was	NULL
induced	NULL
with	NULL
RA	NULL
alone	NULL
.	NULL

The	NULL
response	NULL
to	NULL
1,000	NULL
U/mL	NULL
interferon	NULL
y	NULL
,	NULL
with	NULL
or	NULL
without	NULL
RA	NULL
,	NULL
was	NULL
also	NULL
analyzed	NULL
,	NULL
and	NULL
these	NULL
results	NULL
were	NULL
similar	NULL
,	NULL
but	NULL
with	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3932	NULL
NB4.R1	NULL
NB4.S1	NULL
120	NULL
160	NULL
200	NULL
i	NULL
120	NULL
160	NULL
200	NULL
i	NULL
CONTROL	NULL
80	NULL
i	NULL
80	NULL
i	NULL
|______._	NULL
ver	NULL
®	NULL
ao	NULL
)	NULL
102	NULL
10°	NULL
10	NULL
o	NULL
bild	NULL
Mt	NULL
er	NULL
*	NULL
°	NULL
ao	NULL
!	NULL

10°	NULL
108	NULL
10	NULL
40	NULL
i	NULL
40	NULL
R	NULL
0	NULL
0	NULL
4	NULL
a	NULL
3	NULL
4	NULL
i	NULL
1	NULL
120	NULL
160	NULL
200	NULL
i	NULL
120	NULL
160	NULL
200	NULL
i	NULL
RA	NULL
80	NULL
i	NULL
80	NULL
i	NULL
40	NULL
a	NULL
0	NULL
i	NULL
0	NULL
0	NULL
9	NULL
eT	NULL
wr	NULL
*	NULL
102	NULL
19°	NULL
r	NULL
102	NULL
10	NULL
°	NULL
19	NULL
``	NULL
>	NULL
t	NULL
10	NULL
10	NULL
10	NULL
l	NULL
10°	NULL
10	NULL
aid	NULL
a	NULL
i	NULL
120	NULL
160	NULL
200	NULL
i	NULL
IFN	NULL
80	NULL
120	NULL
160	NULL
200	NULL
i	NULL
80	NULL
i	NULL
40	NULL
i	NULL
40	NULL
0	NULL
0	NULL
=t	NULL
m	NULL
ht	NULL
h	NULL
u	NULL
105	NULL
402	NULL
140°	NULL
10	NULL
10	NULL
'	NULL
4	NULL
er	NULL
0	NULL
102	NULL
10	NULL
%	NULL
10*	NULL
aa	NULL
o	NULL
o	NULL
120	NULL
160	NULL
200	NULL
a	NULL
i	NULL
120	NULL
160	NULL
200	NULL
i	NULL
RA+IFN	NULL
$	NULL
1	NULL
9	NULL
74	NULL
|	NULL
04	NULL
10	NULL
40	NULL
-	NULL
60	NULL
dijuadal	NULL
0	NULL
an	NULL
!	NULL

10°	NULL
10	NULL
*	NULL
mira	NULL
10°	NULL
10°	NULL
10	NULL
0	NULL
Fig	NULL
4	NULL
.	NULL

Mo-1	NULL
expression	NULL
of	NULL
NB4-R1	NULL
and	NULL
NB4-S1	NULL
cells	NULL
induced	NULL
by	NULL
RA	NULL
and	NULL
IFNy	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
for	NULL
5	NULL
days	NULL
with	NULL
10°	NULL
mol/L	NULL
RA	NULL
,	NULL
100	NULL
U/mL	NULL
IFNy	NULL
,	NULL
or	NULL
10°	NULL
mol/L	NULL
RA	NULL
+	NULL
100	NULL
U/mL	NULL
IFNy	NULL
.	NULL

Cells	NULL
incubated	NULL
in	NULL
vehicle	NULL
(	NULL
DMSO	NULL
1:10°	NULL
dilution	NULL
)	NULL
were	NULL
used	NULL
as	NULL
a	NULL
control	NULL
.	NULL

The	NULL
Y-axis	NULL
indicates	NULL
cell	NULL
number	NULL
and	NULL
the	NULL
X-axis	NULL
indicates	NULL
mean	NULL
fluoresence	NULL
.	NULL

The	NULL
bar	NULL
in	NULL
each	NULL
indicates	NULL
the	NULL
population	NULL
gated	NULL
for	NULL
the	NULL
count	NULL
.	NULL

The	NULL
isotypic	NULL
control	NULL
is	NULL
not	NULL
shown	NULL
,	NULL
as	NULL
there	NULL
was	NULL
no	NULL
background	NULL
fluorescence	NULL
.	NULL

a	NULL
slightly	NULL
enhanced	NULL
response	NULL
in	NULL
all	NULL
cases	NULL
compared	NULL
with	NULL
100	NULL
U/mL	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
Mo-1	NULL
expression	NULL
in	NULL
NB4-R1	NULL
and	NULL
NB4-S1	NULL
cells	NULL
grown	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
U/	NULL
mL	NULL
and	NULL
1,000	NULL
U/mL	NULL
interferon	NULL
a	NULL
and	NULL
3	NULL
,	NULL
with	NULL
and	NULL
without	NULL
RA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
was	NULL
studied	NULL
.	NULL

None	NULL
of	NULL
these	NULL
treatment	NULL
conditions	NULL
,	NULL
in	NULL
either	NULL
cell	NULL
,	NULL
showed	NULL
a	NULL
response	NULL
to	NULL
interferon	NULL
or	NULL
an	NULL
enhanced	NULL
response	NULL
to	NULL
RA	NULL
.	NULL

The	NULL
NBT	NULL
assay	NULL
was	NULL
also	NULL
used	NULL
to	NULL
assess	NULL
maturation	NULL
of	NULL
NB4-R1	NULL
and	NULL
NB4-S1	NULL
cells	NULL
before	NULL
and	NULL
after	NULL
the	NULL
same	NULL
treatment	NULL
combinations	NULL
.	NULL

These	NULL
data	NULL
independently	NULL
confirmed	NULL
that	NULL
interferon	NULL
y	NULL
induced	NULL
NB4-R1	NULL
cells	NULL
to	NULL
differentiate	NULL
,	NULL
and	NULL
,	NULL
in	NULL
combination	NULL
with	NULL
RA	NULL
,	NULL
there	NULL
was	NULL
at	NULL
least	NULL
an	NULL
additive	NULL
matura-	NULL
NASON-BURCHENAL	NULL
ET	NULL
AL	NULL
tion	NULL
effect	NULL
.	NULL

Figure	NULL
5	NULL
depicts	NULL
the	NULL
percentage	NULL
of	NULL
NB4-R1	NULL
and	NULL
NB4-S1	NULL
cells	NULL
that	NULL
reduce	NULL
NBT	NULL
after	NULL
treatment	NULL
with	NULL
100	NULL
U/	NULL
mL	NULL
interferon	NULL
y	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
RA	NULL
.	NULL

Data	NULL
in	NULL
Fig	NULL
5A	NULL
show	NULL
that	NULL
after	NULL
5	NULL
days	NULL
of	NULL
treatment	NULL
,	NULL
NB4-S1	NULL
cells	NULL
were	NULL
responsive	NULL
to	NULL
RA	NULL
(	NULL
69	NULL
%	NULL
NBT-positive	NULL
)	NULL
,	NULL
but	NULL
had	NULL
no	NULL
response	NULL
to	NULL
interferon	NULL
y	NULL
alone	NULL
(	NULL
1.5	NULL
%	NULL
NBT-positive	NULL
)	NULL
.	NULL

There	NULL
was	NULL
not	NULL
an	NULL
enhanced	NULL
effect	NULL
with	NULL
the	NULL
combined	NULL
treatment	NULL
(	NULL
73	NULL
%	NULL
NBT-positive	NULL
)	NULL
.	NULL

At	NULL
day	NULL
5	NULL
,	NULL
there	NULL
was	NULL
almost	NULL
maximal	NULL
differentiation	NULL
achieved	NULL
in	NULL
NB4-S1	NULL
cells	NULL
treated	NULL
with	NULL
RA	NULL
alone	NULL
.	NULL

To	NULL
establish	NULL
whether	NULL
interferon	NULL
y	NULL
augmented	NULL
RA	NULL
actions	NULL
but	NULL
was	NULL
masked	NULL
by	NULL
the	NULL
already	NULL
high	NULL
response	NULL
rate	NULL
of	NULL
NB4-S1	NULL
cells	NULL
,	NULL
the	NULL
NBT	NULL
assay	NULL
was	NULL
performed	NULL
on	NULL
day	NULL
3	NULL
.	NULL

These	NULL
results	NULL
showed	NULL
that	NULL
NB4-S1	NULL
cells	NULL
treated	NULL
with	NULL
RA	NULL
alone	NULL
and	NULL
RA	NULL
plus	NULL
100	NULL
U/mL	NULL
interferon	NULL
y	NULL
still	NULL
exhibited	NULL
similar	NULL
differentiation	NULL
(	NULL
19	NULL
%	NULL
and	NULL
20	NULL
%	NULL
NBT-positive	NULL
,	NULL
respectively	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
NB4-R1	NULL
cells	NULL
were	NULL
responsive	NULL
to	NULL
100	NULL
U/mL	NULL
interferon	NULL
y	NULL
(	NULL
14	NULL
%	NULL
NBT-positive	NULL
)	NULL
;	NULL
and	NULL
had	NULL
a	NULL
negligible	NULL
RA	NULL
response	NULL
(	NULL
3.8	NULL
%	NULL
NBT-positive	NULL
)	NULL
.	NULL

A	NULL
superadditive	NULL
effect	NULL
with	NULL
the	NULL
combination	NULL
of	NULL
RA	NULL
plus	NULL
interferon	NULL
y	NULL
(	NULL
28	NULL
%	NULL
NBT-positive	NULL
)	NULL
was	NULL
observed	NULL
.	NULL

A	NULL
greater	NULL
response	NULL
occurred	NULL
when	NULL
NB4-R1	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
1,000	NULL
U/mL	NULL
interferon	NULL
y	NULL
alone	NULL
(	NULL
22	NULL
%	NULL
NBT-positive	NULL
)	NULL
and	NULL
with	NULL
RA	NULL
plus	NULL
1,000	NULL
U/mL	NULL
interferon	NULL
y	NULL
(	NULL
40	NULL
%	NULL
NBT-positive	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Interferon	NULL
a	NULL
,	NULL
3	NULL
,	NULL
and	NULL
y	NULL
,	NULL
did	NULL
not	NULL
exert	NULL
an	NULL
appreciable	NULL
effect	NULL
on	NULL
the	NULL
RA	NULL
response	NULL
of	NULL
RA-sensitive	NULL
cells	NULL
,	NULL
except	NULL
in	NULL
the	NULL
treatment	NULL
arm	NULL
of	NULL
1,000	NULL
U/mL	NULL
interferon	NULL
a	NULL
plus	NULL
RA	NULL
,	NULL
when	NULL
NBT-positive	NULL
cells	NULL
increased	NULL
slightly	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Due	NULL
to	NULL
the	NULL
ability	NULL
of	NULL
interferon	NULL
y	NULL
to	NULL
differentiate	NULL
NB4-R	NULL
1	NULL
cells	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
interferon	NULL
y	NULL
on	NULL
proliferation	NULL
of	NULL
NB4-R	NULL
I	NULL
and	NULL
NB4-S1	NULL
cells	NULL
was	NULL
assessed	NULL
by	NULL
MTT	NULL
assay	NULL
.	NULL
``	NULL

The	NULL
MTT	NULL
assay	NULL
was	NULL
used	NULL
in	NULL
studies	NULL
of	NULL
NB4-R1	NULL
and	NULL
NB4-S1	NULL
cells	NULL
to	NULL
facilitate	NULL
analysis	NULL
of	NULL
multiple	NULL
treatment	NULL
combinations	NULL
.	NULL

This	NULL
assay	NULL
is	NULL
more	NULL
rapid	NULL
than	NULL
manual	NULL
cell	NULL
counts	NULL
determined	NULL
by	NULL
hemocytometer	NULL
.	NULL

Figure	NULL
3C	NULL
shows	NULL
that	NULL
100	NULL
U/mL	NULL
interferon	NULL
y	NULL
alone	NULL
had	NULL
a	NULL
slight	NULL
inhibitory	NULL
effect	NULL
on	NULL
proliferation	NULL
of	NULL
NB4-R1	NULL
cells	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
100	NULL
U/mL	NULL
interferon	NULL
y	NULL
plus	NULL
RA	NULL
led	NULL
to	NULL
a	NULL
substantial	NULL
decrease	NULL
in	NULL
proliferation	NULL
by	NULL
day	NULL
5	NULL
.	NULL

These	NULL
results	NULL
were	NULL
even	NULL
more	NULL
notable	NULL
in	NULL
the	NULL
combination	NULL
of	NULL
1,000	NULL
U/mL	NULL
interferon	NULL
y	NULL
plus	NULL
RA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Con-versely	NULL
,	NULL
interferon	NULL
y	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
NB4-S1	NULL
cells	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
RA	NULL
plus	NULL
either	NULL
100	NULL
U/mL	NULL
or	NULL
1,000	NULL
U/mL	NULL
interferon	NULL
y	NULL
was	NULL
similar	NULL
to	NULL
RA	NULL
treatment	NULL
alone	NULL
(	NULL
Fig	NULL
3A	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
interferon	NULL
y	NULL
overcomes	NULL
de	NULL
novo	NULL
resistance	NULL
to	NULL
the	NULL
growth	NULL
inhibitory	NULL
and	NULL
differentiation	NULL
properties	NULL
of	NULL
RA	NULL
in	NULL
NB4-R1	NULL
cells	NULL
.	NULL

At	NULL
the	NULL
dose	NULL
of	NULL
100	NULL
U/mL	NULL
interferon	NULL
y	NULL
,	NULL
a	NULL
level	NULL
achievable	NULL
in	NULL
patients	NULL
,	NULL
myeloid	NULL
maturation	NULL
occurred	NULL
in	NULL
NB4-R1	NULL
cells	NULL
,	NULL
and	NULL
when	NULL
combined	NULL
with	NULL
RA	NULL
,	NULL
effects	NULL
were	NULL
at	NULL
least	NULL
additive	NULL
.	NULL

At	NULL
the	NULL
higher	NULL
interferon	NULL
levels	NULL
,	NULL
1,000	NULL
U/	NULL
mL	NULL
,	NULL
this	NULL
response	NULL
was	NULL
enhanced	NULL
.	NULL

Interferon	NULL
a	NULL
or	NULL
3	NULL
treatments	NULL
did	NULL
not	NULL
induce	NULL
growth	NULL
arrest	NULL
or	NULL
differentiation	NULL
of	NULL
NB4-R	NULL
I1	NULL
cells	NULL
.	NULL

DISCUSSION	NULL
The	NULL
PML	NULL
gene	NULL
of	NULL
APL	NULL
is	NULL
a	NULL
nuclear	NULL
protein	NULL
whose	NULL
speckled	NULL
distribution	NULL
within	NULL
the	NULL
nucleus	NULL
is	NULL
altered	NULL
after	NULL
exposure	NULL
to	NULL
various	NULL
stimuli	NULL
,	NULL
including	NULL
viral	NULL
infection	NULL
,	NULL
heat	NULL
shock	NULL
,	NULL
in-flammation	NULL
,	NULL
and	NULL
tumor	NULL
progression	NULL
(	NULL
our	NULL
unpublished	NULL
re	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IFN	NULL
AND	NULL
RA-RESISTANCE	NULL
IN	NULL
APL	NULL
A	NULL
3933	NULL
NB4-S1	NULL
%	NULL
NBT	NULL
POSITIVE	NULL
RA	NULL
+	NULL
IFN	NULL
TREATMENT	NULL
NB4-R1	NULL
80	NULL
;	NULL
70	NULL
1	NULL
@	NULL
_	NULL
60	NULL
1	NULL
a	NULL
8	NULL
50	NULL
&	NULL
ge	NULL
40	NULL
7	NULL
-	NULL
|	NULL
*	NULL
39+	NULL
&	NULL
|	NULL
20	NULL
]	NULL
CONTROL	NULL
RA	NULL
IFN	NULL
RA	NULL
+	NULL
IFN	NULL
TREATMENT	NULL
Fig	NULL
5	NULL
.	NULL

NBT	NULL
assay	NULL
of	NULL
NB4-S1	NULL
and	NULL
NB4-R1	NULL
cells	NULL
cultured	NULL
in	NULL
RA	NULL
and/or	NULL
IFNy	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
for	NULL
5	NULL
days	NULL
in	NULL
no	NULL
treatment	NULL
(	NULL
control	NULL
}	NULL
,	NULL
10°	NULL
mol/	NULL
L	NULL
RA	NULL
,	NULL
100	NULL
U/mL	NULL
IFNy	NULL
,	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
RA	NULL
+	NULL
IFNy	NULL
.	NULL

NBT	NULL
assays	NULL
were	NULL
performed	NULL
on	NULL
day	NULL
5	NULL
.	NULL

The	NULL
X-axis	NULL
indicates	NULL
the	NULL
treatment	NULL
group	NULL
.	NULL

The	NULL
Y-axis	NULL
is	NULL
the	NULL
percent	NULL
NBT-positive	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
NB4-S1	NULL
cells	NULL
and	NULL
(	NULL
B	NULL
)	NULL
NB4-R1	NULL
cells	NULL
.	NULL

sults	NULL
)	NULL
.	NULL

``	NULL
``	NULL
>	NULL
'	NULL
Different	NULL
PML	NULL
isoforms	NULL
are	NULL
expressed	NULL
within	NULL
tissues	NULL
and	NULL
cell	NULL
lines	NULL
from	NULL
different	NULL
histologic	NULL
origin	NULL
.	NULL

In	NULL
the	NULL
bone	NULL
marrow	NULL
,	NULL
PML	NULL
expression	NULL
is	NULL
restricted	NULL
to	NULL
the	NULL
myeloid	NULL
compartment	NULL
.	NULL

``	NULL
°	NULL
Activated	NULL
macrophages	NULL
accumulate	NULL
PML	NULL
protein	NULL
in	NULL
the	NULL
nuclear	NULL
bodies	NULL
.	NULL
``	NULL

''	NULL
Class	NULL
I	NULL
and	NULL
II	NULL
interferons	NULL
transcriptionally	NULL
induce	NULL
PML	NULL
in	NULL
several	NULL
cell	NULL
lines	NULL
.	NULL
``	NULL

''	NULL
This	NULL
study	NULL
examined	NULL
whether	NULL
interferon	NULL
regulates	NULL
PML	NULL
expression	NULL
in	NULL
normal	NULL
circulating	NULL
myeloid	NULL
cells	NULL
.	NULL

Notably	NULL
,	NULL
PML	NULL
is	NULL
not	NULL
appreciably	NULL
expressed	NULL
in	NULL
mature	NULL
circulating	NULL
myeloid	NULL
cells	NULL
.	NULL

This	NULL
finding	NULL
,	NULL
combined	NULL
with	NULL
the	NULL
observation	NULL
that	NULL
PML	NULL
is	NULL
highly	NULL
expressed	NULL
in	NULL
bone	NULL
marrow	NULL
cells	NULL
of	NULL
myeloid	NULL
lineage	NULL
and	NULL
in	NULL
APL	NULL
promyelocytes	NULL
,	NULL
suggests	NULL
PML	NULL
expression	NULL
declines	NULL
when	NULL
neutrophils	NULL
and	NULL
monocytes	NULL
mature	NULL
.	NULL

``	NULL
**	NULL
``	NULL
These	NULL
cells	NULL
reactivate	NULL
PML	NULL
expression	NULL
after	NULL
stimulation	NULL
with	NULL
specific	NULL
cytokines	NULL
.	NULL

A	NULL
cytokine	NULL
active	NULL
in	NULL
this	NULL
effect	NULL
is	NULL
interferon	NULL
that	NULL
is	NULL
able	NULL
to	NULL
induce	NULL
PML	NULL
expression	NULL
within	NULL
a	NULL
few	NULL
hours	NULL
of	NULL
treatment	NULL
(	NULL
Fig	NULL
1	NULL
)	NULL
.	NULL

Regulated	NULL
PML	NULL
expression	NULL
by	NULL
interferon	NULL
occurs	NULL
in	NULL
terminally	NULL
differentiated	NULL
myeloid	NULL
cells	NULL
in	NULL
a	NULL
cell-type-spe-cific	NULL
manner	NULL
.	NULL

In	NULL
PMNs	NULL
,	NULL
PML-3	NULL
isoform	NULL
is	NULL
not	NULL
augmented	NULL
by	NULL
interferon	NULL
to	NULL
levels	NULL
comparable	NULL
to	NULL
other	NULL
isoforms	NULL
,	NULL
whereas	NULL
in	NULL
monocytes	NULL
all	NULL
PML	NULL
isoforms	NULL
are	NULL
induced	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
.	NULL

Immunofluorescence	NULL
studies	NULL
showed	NULL
that	NULL
after	NULL
interferon	NULL
stimulation	NULL
,	NULL
PML	NULL
not	NULL
only	NULL
localizes	NULL
to	NULL
the	NULL
nuclear	NULL
speckles	NULL
of	NULL
circulating	NULL
monocytes	NULL
,	NULL
but	NULL
also	NULL
accumulates	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
these	NULL
cells	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
interferon-stimulated	NULL
PMNs	NULL
have	NULL
PML	NULL
distributed	NULL
in	NULL
a	NULL
typical	NULL
nuclear	NULL
speckled	NULL
pattern	NULL
.	NULL

Upon	NULL
interferon	NULL
stimulation	NULL
,	NULL
PML	NULL
is	NULL
upregulated	NULL
in	NULL
circulating	NULL
lymphocytes	NULL
,	NULL
where	NULL
it	NULL
accumulates	NULL
in	NULL
the	NULL
nuclear	NULL
bodies	NULL
and	NULL
throughout	NULL
the	NULL
nucleus	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

If	NULL
PML	NULL
functions	NULL
in	NULL
negatively	NULL
regulating	NULL
cell	NULL
growth	NULL
,	NULL
then	NULL
PML	NULL
may	NULL
be	NULL
necessary	NULL
during	NULL
terminal	NULL
maturation	NULL
;	NULL
however	NULL
,	NULL
once	NULL
a	NULL
mature	NULL
circulating	NULL
blood	NULL
cell	NULL
no	NULL
longer	NULL
proliferates	NULL
,	NULL
PML	NULL
could	NULL
acquire	NULL
a	NULL
different	NULL
role	NULL
,	NULL
one	NULL
that	NULL
is	NULL
dependent	NULL
on	NULL
interferon	NULL
stimulation	NULL
,	NULL
such	NULL
as	NULL
functional	NULL
activation	NULL
during	NULL
viral	NULL
or	NULL
bacterial	NULL
infections	NULL
.	NULL

Interferon	NULL
also	NULL
induces	NULL
PML	NULL
and	NULL
PML/RARa	NULL
expression	NULL
in	NULL
NB4	NULL
APL	NULL
cells	NULL
and	NULL
in	NULL
some	NULL
APL	NULL
cells	NULL
from	NULL
patients	NULL
(	NULL
Fig	NULL
2	NULL
and	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
the	NULL
interferon	NULL
regulatory	NULL
elements	NULL
within	NULL
PML	NULL
are	NULL
not	NULL
lost	NULL
when	NULL
PML	NULL
fuses	NULL
to	NULL
RARa	NULL
,	NULL
and	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
interferon	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
controlling	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
APL	NULL
blasts	NULL
by	NULL
regulating	NULL
PML	NULL
or	NULL
PML/RARa	NULL
expression	NULL
.	NULL

Based	NULL
on	NULL
this	NULL
assumption	NULL
,	NULL
we	NULL
treated	NULL
NB4	NULL
cells	NULL
with	NULL
class	NULL
I	NULL
and	NULL
II	NULL
interferons	NULL
.	NULL

Because	NULL
APL	NULL
blasts	NULL
mature	NULL
in	NULL
response	NULL
to	NULL
RA	NULL
treatment	NULL
,	NULL
interferon	NULL
effects	NULL
in	NULL
these	NULL
cells	NULL
were	NULL
examined	NULL
alone	NULL
and	NULL
in	NULL
combination	NULL
with	NULL
RA	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
not	NULL
appreciably	NULL
affected	NULL
by	NULL
treatment	NULL
with	NULL
interferon	NULL
and	NULL
RA	NULL
alone	NULL
(	NULL
Fig	NULL
3	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
interferon	NULL
and	NULL
RA	NULL
exert	NULL
a	NULL
synergistic	NULL
cytotoxic	NULL
effect	NULL
when	NULL
administered	NULL
together	NULL
,	NULL
with	NULL
interferon	NULL
3	NULL
being	NULL
more	NULL
effective	NULL
than	NULL
either	NULL
a	NULL
or	NULL
y	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
.	NULL

RA	NULL
treatment	NULL
exerts	NULL
an	NULL
antiproliferative	NULL
effect	NULL
,	NULL
with	NULL
a	NULL
maximal	NULL
response	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10°	NULL
mol/L	NULL
(	NULL
80	NULL
%	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

At	NULL
clinically	NULL
achievable	NULL
doses	NULL
,	NULL
interferon	NULL
also	NULL
suppresses	NULL
growth	NULL
of	NULL
APL	NULL
cells	NULL
.	NULL

The	NULL
three	NULL
interferons	NULL
examined	NULL
inhibit	NULL
cell	NULL
growth	NULL
in	NULL
a	NULL
similar	NULL
manner	NULL
,	NULL
with	NULL
a	NULL
maximal	NULL
inhibition	NULL
of	NULL
30	NULL
%	NULL
to	NULL
40	NULL
%	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
.	NULL

When	NULL
NB4	NULL
cells	NULL
are	NULL
treated	NULL
with	NULL
interferon	NULL
(	NULL
100	NULL
U/mL	NULL
)	NULL
plus	NULL
RA	NULL
(	NULL
10°	NULL
mol/	NULL
L	NULL
)	NULL
,	NULL
greater	NULL
growth	NULL
suppression	NULL
occurs	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
.	NULL

The	NULL
interferons	NULL
studied	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
RA	NULL
show	NULL
,	NULL
in	NULL
NB4	NULL
cells	NULL
,	NULL
at	NULL
least	NULL
an	NULL
additive	NULL
antiproliferative	NULL
effect	NULL
.	NULL

Interferon	NULL
alone	NULL
has	NULL
negligible	NULL
differentiation-inducing	NULL
capacity	NULL
on	NULL
NB4-S1	NULL
cells	NULL
,	NULL
which	NULL
retain	NULL
the	NULL
ability	NULL
to	NULL
differentiate	NULL
upon	NULL
exposure	NULL
to	NULL
RA	NULL
(	NULL
Figs	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Surpris-ingly	NULL
,	NULL
when	NULL
interferon	NULL
y	NULL
alone	NULL
was	NULL
tested	NULL
at	NULL
pharmacologic	NULL
doses	NULL
on	NULL
NB4	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
refractory	NULL
to	NULL
the	NULL
maturative	NULL
effects	NULL
of	NULL
RA	NULL
(	NULL
NB4-R1	NULL
)	NULL
,	NULL
15	NULL
%	NULL
to	NULL
20	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
differentiated	NULL
as	NULL
established	NULL
by	NULL
the	NULL
NBT	NULL
assay	NULL
and	NULL
flow-cytometric	NULL
analysis	NULL
of	NULL
myeloid	NULL
surface	NULL
markers	NULL
(	NULL
Figs	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Interferon	NULL
a	NULL
and	NULL
3	NULL
treatments	NULL
alone	NULL
did	NULL
not	NULL
exert	NULL
appreciable	NULL
maturation	NULL
responses	NULL
in	NULL
either	NULL
NB4-S1	NULL
or	NULL
NB4-R1	NULL
cells	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3934	NULL
Interferon	NULL
y	NULL
partially	NULL
restored	NULL
RA	NULL
response	NULL
of	NULL
NB4-R	NULL
1	NULL
cells	NULL
,	NULL
as	NULL
seen	NULL
by	NULL
the	NULL
more	NULL
than	NULL
additive	NULL
effect	NULL
of	NULL
the	NULL
combination	NULL
treatment	NULL
.	NULL

The	NULL
capacity	NULL
of	NULL
interferon	NULL
to	NULL
promote	NULL
growth	NULL
inhibition	NULL
,	NULL
cytotoxicity	NULL
,	NULL
and	NULL
differentiation	NULL
of	NULL
myeloid	NULL
cells	NULL
has	NULL
been	NULL
investigated	NULL
primarily	NULL
with	NULL
cell	NULL
lines	NULL
such	NULL
as	NULL
HL60	NULL
and	NULL
U937	NULL
that	NULL
do	NULL
not	NULL
carry	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
specific	NULL
to	NULL
APL	NULL
.	NULL

****	NULL
The	NULL
findings	NULL
of	NULL
this	NULL
study	NULL
extend	NULL
prior	NULL
work	NULL
exploring	NULL
the	NULL
role	NULL
of	NULL
interferon	NULL
in	NULL
APL	NULL
cells	NULL
``	NULL
``	NULL
``	NULL
``	NULL
by	NULL
reporting	NULL
a	NULL
comprehensive	NULL
analysis	NULL
of	NULL
interferon	NULL
effects	NULL
in	NULL
normal	NULL
hematopoietic	NULL
cells	NULL
,	NULL
fresh	NULL
APL	NULL
cells	NULL
from	NULL
patients	NULL
,	NULL
and	NULL
RA-sensitive	NULL
and	NULL
-resis-tant	NULL
NB4	NULL
cells	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
view	NULL
that	NULL
interferons	NULL
play	NULL
a	NULL
role	NULL
in	NULL
normal	NULL
and	NULL
pathological	NULL
myeloid	NULL
hematopoiesis	NULL
by	NULL
augmenting	NULL
signals	NULL
that	NULL
regulate	NULL
commitment	NULL
,	NULL
maturation	NULL
,	NULL
and	NULL
expansion	NULL
of	NULL
myeloid	NULL
precursors	NULL
,	NULL
thereby	NULL
modulating	NULL
the	NULL
expression	NULL
of	NULL
different	NULL
genes	NULL
,	NULL
including	NULL
PML	NULL
.	NULL

Interferon	NULL
acts	NULL
in	NULL
a	NULL
specific	NULL
manner	NULL
in	NULL
APL	NULL
,	NULL
where	NULL
it	NULL
upregulates	NULL
PML/RARa	NULL
and	NULL
PML	NULL
and	NULL
partially	NULL
restores	NULL
differentiation	NULL
sensitivity	NULL
in	NULL
an	NULL
RA-resistant	NULL
NB4	NULL
APL	NULL
cell	NULL
.	NULL

Grignani	NULL
et	NULL
al	NULL
have	NULL
shown	NULL
that	NULL
PML/RARa	NULL
blocks	NULL
differentiation	NULL
of	NULL
U937	NULL
myeloid	NULL
cells	NULL
,	NULL
but	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
pharmacologic	NULL
doses	NULL
of	NULL
RA	NULL
,	NULL
promotes	NULL
differentiation	NULL
of	NULL
these	NULL
cells	NULL
.	NULL
``	NULL

''	NULL
``	NULL
'	NULL
Based	NULL
on	NULL
these	NULL
results	NULL
,	NULL
they	NULL
proposed	NULL
a	NULL
model	NULL
by	NULL
which	NULL
the	NULL
PML/RARa	NULL
fusion	NULL
protein	NULL
is	NULL
leukemogenic	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
RA	NULL
,	NULL
but	NULL
promotes	NULL
terminal	NULL
differentiation	NULL
of	NULL
APL	NULL
promyelocytic	NULL
blasts	NULL
if	NULL
RA	NULL
is	NULL
present	NULL
.	NULL
``	NULL

''	NULL
If	NULL
this	NULL
model	NULL
is	NULL
correct	NULL
,	NULL
then	NULL
one	NULL
way	NULL
to	NULL
explain	NULL
the	NULL
results	NULL
reported	NULL
here	NULL
is	NULL
to	NULL
postulate	NULL
that	NULL
PML/RARa	NULL
expression	NULL
is	NULL
augmented	NULL
by	NULL
interferon	NULL
and	NULL
with	NULL
pharmacologic	NULL
RA	NULL
doses	NULL
promotes	NULL
the	NULL
differentiation	NULL
of	NULL
APL	NULL
blasts	NULL
.	NULL

Notably	NULL
,	NULL
a	NULL
PML/RARa	NULL
protein	NULL
of	NULL
expected	NULL
size	NULL
is	NULL
found	NULL
by	NULL
Western	NULL
analysis	NULL
of	NULL
the	NULL
NB4-Rl	NULL
RA-resistant	NULL
line	NULL
we	NULL
have	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
interferon	NULL
may	NULL
promote	NULL
differentiation	NULL
by	NULL
modulating	NULL
the	NULL
expression	NULL
of	NULL
PML	NULL
isoforms	NULL
.	NULL

Yet	NULL
,	NULL
neither	NULL
of	NULL
these	NULL
interpretations	NULL
fully	NULL
accounts	NULL
for	NULL
the	NULL
preferential	NULL
effects	NULL
of	NULL
interferon	NULL
y	NULL
,	NULL
which	NULL
,	NULL
if	NULL
compared	NULL
with	NULL
a	NULL
and	NULL
B	NULL
,	NULL
appears	NULL
most	NULL
effective	NULL
in	NULL
promoting	NULL
differentiation	NULL
of	NULL
NB4-resistant	NULL
cells	NULL
.	NULL

In	NULL
one	NULL
clinical	NULL
APL	NULL
case	NULL
,	NULL
the	NULL
use	NULL
of	NULL
interferon	NULL
successfully	NULL
overcame	NULL
RA	NULL
resistance	NULL
in	NULL
vivo	NULL
.	NULL
``	NULL

'	NULL
In	NULL
another	NULL
case	NULL
,	NULL
interferon	NULL
did	NULL
not	NULL
overcome	NULL
retinoid	NULL
resistance	NULL
,	NULL
``	NULL
but	NULL
the	NULL
interferons	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
differed	NULL
and	NULL
neither	NULL
study	NULL
used	NULL
interferon	NULL
y	NULL
.	NULL

From	NULL
the	NULL
studies	NULL
reported	NULL
here	NULL
,	NULL
it	NULL
is	NULL
apparent	NULL
that	NULL
additional	NULL
in	NULL
vitro	NULL
studies	NULL
are	NULL
needed	NULL
to	NULL
pursue	NULL
the	NULL
mechanisms	NULL
responsible	NULL
for	NULL
this	NULL
cooperation	NULL
before	NULL
additional	NULL
clinical	NULL
trials	NULL
are	NULL
undertaken	NULL
.	NULL

It	NULL
would	NULL
be	NULL
worthwhile	NULL
to	NULL
learn	NULL
whether	NULL
interferons	NULL
can	NULL
induce	NULL
growth	NULL
suppression	NULL
or	NULL
maturation	NULL
of	NULL
other	NULL
RA-resistant	NULL
NB4	NULL
lines	NULL
,	NULL
especially	NULL
NB4-resistant	NULL
cells	NULL
where	NULL
the	NULL
PML/RARa	NULL
chimeric	NULL
protein	NULL
is	NULL
not	NULL
found	NULL
.	NULL
``	NULL

This	NULL
study	NULL
has	NULL
highlighted	NULL
a	NULL
potential	NULL
role	NULL
for	NULL
interferon	NULL
y	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
retinoid	NULL
resistant	NULL
APL	NULL
.	NULL

Yet	NULL
interferons	NULL
a	NULL
and	NULL
#	NULL
may	NULL
also	NULL
play	NULL
a	NULL
role	NULL
in	NULL
other	NULL
APL	NULL
cases	NULL
.	NULL

It	NULL
would	NULL
be	NULL
interesting	NULL
to	NULL
examine	NULL
whether	NULL
interferons	NULL
are	NULL
clinically	NULL
active	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
RA	NULL
in	NULL
APL	NULL
patients	NULL
characterized	NULL
by	NULL
variant	NULL
translocations	NULL
such	NULL
as	NULL
the	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
associated	NULL
with	NULL
a	NULL
de	NULL
novo	NULL
resistance	NULL
to	NULL
RA	NULL
.	NULL
``	NULL

It	NULL
remains	NULL
to	NULL
be	NULL
explored	NULL
if	NULL
treating	NULL
APL	NULL
patients	NULL
,	NULL
at	NULL
pre-	NULL
NASON-BURCHENAL	NULL
ET	NULL
AL	NULL
sentation	NULL
,	NULL
with	NULL
a	NULL
retinoid	NULL
plus	NULL
interferon	NULL
regimen	NULL
could	NULL
increase	NULL
the	NULL
proportion	NULL
of	NULL
cells	NULL
undergoing	NULL
terminal	NULL
differenti-ation	NULL
,	NULL
and	NULL
thereby	NULL
enhance	NULL
chemotherapeutic	NULL
response	NULL
.	NULL

Transgenic	NULL
mouse	NULL
models	NULL
of	NULL
APL	NULL
carrying	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
products	NULL
,	NULL
would	NULL
be	NULL
extremely	NULL
useful	NULL
in	NULL
addressing	NULL
these	NULL
questions	NULL
.	NULL

ACKNOWLEDGMENT	NULL
We	NULL
thank	NULL
Dr	NULL
M.	NULL
Lanotte	NULL
for	NULL
the	NULL
original	NULL
NB4	NULL
cell	NULL
line	NULL
,	NULL
Dr	NULL
P.	NULL
Chambon	NULL
for	NULL
the	NULL
RARa	NULL
antibody	NULL
,	NULL
Dr	NULL
P.G	NULL
.	NULL

Pelicci	NULL
for	NULL
the	NULL
PM-G3	NULL
antibody	NULL
,	NULL
and	NULL
Dr	NULL
L.	NULL
Luzzatto	NULL
for	NULL
helpful	NULL
discussions	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Bennett	NULL
JM	NULL
,	NULL
Catovsky	NULL
D	NULL
,	NULL
Daniel	NULL
D	NULL
,	NULL
Flandrin	NULL
G	NULL
,	NULL
Galton	NULL
DAG	NULL
,	NULL
Gralnick	NULL
HR	NULL
,	NULL
Sultan	NULL
C	NULL
:	NULL
Proposal	NULL
for	NULL
the	NULL
classification	NULL
of	NULL
the	NULL
acute	NULL
leukaemias	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
33:451	NULL
,	NULL
1976	NULL
2	NULL
.	NULL

Groopman	NULL
J	NULL
,	NULL
Ellman	NULL
L	NULL
:	NULL
Acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Am	NULL
J	NULL
Hematol	NULL
7:395	NULL
,	NULL
1979	NULL
3	NULL
.	NULL

Stone	NULL
RM	NULL
,	NULL
Mayer	NULL
RJ	NULL
:	NULL
The	NULL
unique	NULL
aspects	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
.	NULL

J	NULL
Clin	NULL
Oncol	NULL
8:1913	NULL
,	NULL
1990	NULL
4	NULL
.	NULL

Huang	NULL
M	NULL
,	NULL
Yu-Chen	NULL
Y	NULL
,	NULL
Shu-Rong	NULL
C	NULL
,	NULL
Chai	NULL
J	NULL
,	NULL
Lin	NULL
Z	NULL
,	NULL
Long	NULL
J	NULL
,	NULL
Wang	NULL
Z	NULL
:	NULL
Use	NULL
of	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
72:567	NULL
,	NULL
1988	NULL
5	NULL
.	NULL

Degos	NULL
L	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Danie	NULL
!	NULL

MT	NULL
,	NULL
Berger	NULL
R	NULL
,	NULL
Dombret	NULL
H	NULL
,	NULL
Fenaux	NULL
P	NULL
,	NULL
Castaigne	NULL
S	NULL
:	NULL
Treatment	NULL
of	NULL
first	NULL
relapse	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
with	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
.	NULL

Lancet	NULL
336:1440	NULL
,	NULL
1990	NULL
6	NULL
.	NULL

Warrell	NULL
RP	NULL
Jr	NULL
,	NULL
Frankel	NULL
SR	NULL
,	NULL
Miller	NULL
WH	NULL
Jr	NULL
,	NULL
Scheinberg	NULL
DA	NULL
,	NULL
Itri	NULL
LM	NULL
,	NULL
Hittelman	NULL
WN	NULL
,	NULL
Vyas	NULL
R	NULL
,	NULL
Andreeff	NULL
M	NULL
,	NULL
Tafuri	NULL
A	NULL
,	NULL
Jakubowski	NULL
A	NULL
,	NULL
Gabrilove	NULL
J	NULL
,	NULL
Gordon	NULL
MSS	NULL
,	NULL
Dmitrovsky	NULL
E	NULL
:	NULL
Differentiation	NULL
therapy	NULL
for	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
with	NULL
tretinoin	NULL
(	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
)	NULL
.	NULL

N	NULL
Engl	NULL
J	NULL
Med	NULL
324:1385	NULL
,	NULL
1991	NULL
7	NULL
.	NULL

Fenaux	NULL
P	NULL
,	NULL
Castaigne	NULL
S	NULL
,	NULL
Dombret	NULL
H	NULL
,	NULL
Archimbald	NULL
E	NULL
,	NULL
Duarte	NULL
M	NULL
,	NULL
Morel	NULL
P	NULL
,	NULL
Tilly	NULL
TH	NULL
,	NULL
Guerci	NULL
A	NULL
,	NULL
Maloisel	NULL
F	NULL
,	NULL
Bordessoule	NULL
D	NULL
,	NULL
Sadoun	NULL
A	NULL
,	NULL
Tiberghien	NULL
P	NULL
,	NULL
Fegueux	NULL
N	NULL
,	NULL
Daniel	NULL
MT	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Degos	NULL
L	NULL
:	NULL
All-trans	NULL
retinoic	NULL
acid	NULL
followed	NULL
by	NULL
intensive	NULL
chemotherapy	NULL
gives	NULL
a	NULL
high	NULL
complete	NULL
remission	NULL
rate	NULL
and	NULL
may	NULL
prolong	NULL
remissions	NULL
in	NULL
newly	NULL
diagnosed	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
:	NULL
A	NULL
pilot	NULL
study	NULL
on	NULL
26	NULL
cases	NULL
.	NULL

Blood	NULL
8	NULL
$	NULL
0:2176	NULL
,	NULL
1992	NULL
8	NULL
.	NULL

Castaigne	NULL
S	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Danie	NULL
!	NULL

MT	NULL
,	NULL
Berger	NULL
R	NULL
,	NULL
Fenaux	NULL
P	NULL
,	NULL
Degos	NULL
L	NULL
:	NULL
All-trans	NULL
retinoic	NULL
acid	NULL
as	NULL
a	NULL
differentiating	NULL
therapy	NULL
for	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
I	NULL
.	NULL

Clinical	NULL
results	NULL
.	NULL

Blood	NULL
76:1704	NULL
,	NULL
1990	NULL
9	NULL
.	NULL

Chomienne	NULL
C	NULL
,	NULL
Ballerini	NULL
P	NULL
,	NULL
Balitrand	NULL
N	NULL
,	NULL
Daniel	NULL
MT	NULL
,	NULL
Fenaux	NULL
P	NULL
,	NULL
Castaigne	NULL
S	NULL
,	NULL
Degos	NULL
L	NULL
:	NULL
retinoic	NULL
acid	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemias	NULL
.	NULL

IL	NULL
.	NULL

In	NULL
vitro	NULL
studies	NULL
:	NULL
Structure-function	NULL
relationship	NULL
.	NULL

Blood	NULL
76:1710	NULL
,	NULL
1990	NULL
10.	NULL
de	NULL
Thé	NULL
H	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Lanotte	NULL
M	NULL
,	NULL
Degos	NULL
L	NULL
,	NULL
Dejean	NULL
A	NULL
:	NULL
The	NULL
t	NULL
(	NULL
1	NULL
5	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
fuses	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
gene	NULL
to	NULL
a	NULL
novel	NULL
transcribed	NULL
locus	NULL
.	NULL

Nature	NULL
347:558	NULL
,	NULL
1990	NULL
11	NULL
.	NULL

Borrow	NULL
J	NULL
,	NULL
Goddard	NULL
AD	NULL
,	NULL
Sheer	NULL
D	NULL
,	NULL
Solomon	NULL
E	NULL
:	NULL
Molecular	NULL
analysis	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
breakpoint	NULL
cluster	NULL
region	NULL
on	NULL
chromosome	NULL
17	NULL
.	NULL

Science	NULL
249	NULL
;	NULL
1577	NULL
,	NULL
1990	NULL
12	NULL
.	NULL

Alcalay	NULL
M	NULL
,	NULL
Zangrilli	NULL
D	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Longo	NULL
L	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Giacomucci	NULL
A	NULL
,	NULL
Rocchi	NULL
M	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
Rambaldi	NULL
A	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Diverio	NULL
D	NULL
,	NULL
Donti	NULL
E	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
;	NULL
Translocation	NULL
breakpoint	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
lies	NULL
within	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
locus	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
88:1977	NULL
,	NULL
1991	NULL
13	NULL
.	NULL

Longo	NULL
L	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
Rambaldi	NULL
A	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Diverio	NULL
D	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Donti	NULL
E	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
Rearrangements	NULL
and	NULL
aberrant	NULL
expression	NULL
of	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
gene	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
172:1571	NULL
,	NULL
1990	NULL
14	NULL
.	NULL

Pandolfi	NULL
PP	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
Structure	NULL
and	NULL
origin	NULL
of	NULL
the	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IFN	NULL
AND	NULL
RA-RESISTANCE	NULL
IN	NULL
APL	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
myl/RARa	NULL
cDNA	NULL
and	NULL
characterization	NULL
of	NULL
its	NULL
retinoid-binding	NULL
and	NULL
transactivation	NULL
properties	NULL
.	NULL

Oncogene	NULL
6:1285	NULL
,	NULL
1991	NULL
15	NULL
.	NULL

Kakizuka	NULL
A	NULL
,	NULL
Miller	NULL
WH	NULL
Jr	NULL
,	NULL
Umesono	NULL
K	NULL
,	NULL
Warrell	NULL
RP	NULL
Jr	NULL
,	NULL
Frankel	NULL
SR	NULL
,	NULL
Murty	NULL
VVVS	NULL
,	NULL
Dmitrovsky	NULL
E	NULL
,	NULL
Evans	NULL
RM	NULL
:	NULL
Chromosomal	NULL
translocation	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
in	NULL
human	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
fuses	NULL
RARa	NULL
with	NULL
a	NULL
novel	NULL
putative	NULL
transcription	NULL
factor	NULL
,	NULL
PML	NULL
.	NULL

Cell	NULL
66:663	NULL
,	NULL
1991	NULL
16.	NULL
de	NULL
Thé	NULL
H	NULL
,	NULL
Lavau	NULL
C	NULL
,	NULL
Marehio	NULL
A	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Degos	NULL
L	NULL
,	NULL
Dejean	NULL
A	NULL
:	NULL
The	NULL
PML/RARa	NULL
fusion	NULL
mRNA	NULL
generated	NULL
by	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
encodes	NULL
a	NULL
functionally	NULL
altered	NULL
RAR	NULL
.	NULL

Cell	NULL
66:675	NULL
,	NULL
1991	NULL
17	NULL
.	NULL

Pandolf	NULL
PP	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Zangrilli	NULL
D	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Diverio	NULL
D	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Rambaldi	NULL
A	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Ro-chette-Egly	NULL
C	NULL
,	NULL
Gaube	NULL
MP	NULL
,	NULL
Chambon	NULL
P	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
;	NULL
Genomic	NULL
variability	NULL
and	NULL
alternative	NULL
splicing	NULL
generate	NULL
multiple	NULL
PML/RARa	NULL
transcripts	NULL
that	NULL
encode	NULL
aberrant	NULL
PML	NULL
proteins	NULL
and	NULL
PML/RARa	NULL
isoforms	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

EMBO	NULL
J	NULL
11:1397	NULL
,	NULL
1992	NULL
18	NULL
.	NULL

Alcalay	NULL
M	NULL
,	NULL
Zangrilli	NULL
D	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
Expression	NULL
pattern	NULL
of	NULL
the	NULL
RARa-PML	NULL
fusion	NULL
gene	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
89:4840	NULL
,	NULL
1992	NULL
19	NULL
.	NULL

Grignani	NULL
F	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Longo	NULL
L	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Donti	NULL
E	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
Acute	NULL
promyelocytic	NULL
leukemia	NULL
:	NULL
From	NULL
genetics	NULL
to	NULL
treatment	NULL
.	NULL

Blood	NULL
83:10	NULL
,	NULL
1994	NULL
20	NULL
.	NULL

Perez	NULL
A	NULL
,	NULL
Kastner	NULL
P	NULL
,	NULL
Sethi	NULL
S	NULL
,	NULL
Lutz	NULL
Y	NULL
,	NULL
Reibel	NULL
C	NULL
,	NULL
Chambon	NULL
P	NULL
:	NULL
;	NULL
PML/RAR	NULL
homodimers	NULL
:	NULL
Distinct	NULL
DNA	NULL
binding	NULL
properties	NULL
and	NULL
heteromeric	NULL
interactions	NULL
with	NULL
RXR	NULL
.	NULL

EMBO	NULL
J	NULL
12:3171	NULL
,	NULL
1993	NULL
21	NULL
.	NULL

Grignani	NULL
FR	NULL
,	NULL
Ferrucci	NULL
PF	NULL
,	NULL
Testa	NULL
U	NULL
,	NULL
Talamo	NULL
G	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Peschle	NULL
C	NULL
,	NULL
Nicoletti	NULL
I	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
The	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
specific	NULL
PML/RARa	NULL
fusion	NULL
protein	NULL
inhibits	NULL
differentiation	NULL
and	NULL
promotes	NULL
survival	NULL
of	NULL
myeloid	NULL
precursor	NULL
cells	NULL
.	NULL

Cell	NULL
74:423	NULL
,	NULL
1993	NULL
22	NULL
.	NULL

Chambon	NULL
P	NULL
,	NULL
Zelent	NULL
A	NULL
,	NULL
Petkovich	NULL
M	NULL
,	NULL
Mendelsohn	NULL
C	NULL
,	NULL
Leroy	NULL
P	NULL
,	NULL
Krust	NULL
A	NULL
,	NULL
Kastner	NULL
P	NULL
,	NULL
Brand	NULL
N	NULL
:	NULL
The	NULL
family	NULL
of	NULL
retinoic	NULL
acid	NULL
nuclear	NULL
receptors	NULL
,	NULL
in	NULL
JH	NULL
Saurat	NULL
(	NULL
ed	NULL
)	NULL
;	NULL
Retinoids	NULL
:	NULL
10	NULL
Years	NULL
On	NULL
...	NULL
.	NULL

Basel	NULL
,	NULL
Swit-zerland	NULL
,	NULL
Karger	NULL
,	NULL
1991	NULL
,	NULL
p	NULL
10	NULL
23	NULL
.	NULL

Zelent	NULL
A	NULL
:	NULL
Translocation	NULL
of	NULL
the	NULL
RARa	NULL
locus	NULL
to	NULL
the	NULL
PML	NULL
or	NULL
PLZF	NULL
gene	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
86:451	NULL
,	NULL
1994	NULL
24	NULL
.	NULL

Mu	NULL
ZM	NULL
,	NULL
Chin	NULL
KV	NULL
,	NULL
Liu	NULL
JH	NULL
,	NULL
Lozano	NULL
G	NULL
,	NULL
Chang	NULL
KS	NULL
:	NULL
PML	NULL
,	NULL
a	NULL
growth	NULL
suppressor	NULL
disrupted	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
14:6858	NULL
,	NULL
1994	NULL
25	NULL
.	NULL

Liu	NULL
JH	NULL
,	NULL
Mu	NULL
ZM	NULL
,	NULL
Chang	NULL
KS	NULL
:	NULL
PML	NULL
suppresses	NULL
oncogenic	NULL
transformation	NULL
of	NULL
NIH/3T3	NULL
cells	NULL
by	NULL
activated	NULL
neu	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
181:1965	NULL
,	NULL
1995	NULL
26	NULL
.	NULL

Chang	NULL
KS	NULL
,	NULL
Fan	NULL
YH	NULL
,	NULL
Andreeff	NULL
M	NULL
,	NULL
Liu	NULL
J	NULL
,	NULL
Mu	NULL
ZM	NULL
:	NULL
The	NULL
PML	NULL
gene	NULL
encodes	NULL
a	NULL
phosphoprotein	NULL
associated	NULL
with	NULL
the	NULL
nuclear	NULL
matrix	NULL
.	NULL

Blood	NULL
85:3646	NULL
,	NULL
1995	NULL
27	NULL
.	NULL

Borden	NULL
KLB	NULL
,	NULL
Boddy	NULL
MN	NULL
,	NULL
Lally	NULL
J	NULL
,	NULL
OOReilly	NULL
J	NULL
,	NULL
Martin	NULL
S	NULL
,	NULL
Howe	NULL
K	NULL
,	NULL
Solomon	NULL
E	NULL
,	NULL
Freemont	NULL
PS	NULL
:	NULL
The	NULL
solution	NULL
structure	NULL
of	NULL
the	NULL
RING	NULL
finger	NULL
domain	NULL
from	NULL
the	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
proto-oncoprotein	NULL
PML	NULL
.	NULL

EMBO	NULL
J	NULL
14:1532	NULL
,	NULL
1995	NULL
28	NULL
.	NULL

Koken	NULL
MHM	NULL
,	NULL
Linares-Cruz	NULL
G	NULL
,	NULL
Quignon	NULL
F	NULL
,	NULL
Viron	NULL
A	NULL
,	NULL
Chelbi-Alix	NULL
MK	NULL
,	NULL
Sobczak-Thepot	NULL
J	NULL
,	NULL
Juhlin	NULL
L	NULL
,	NULL
Degos	NULL
L	NULL
,	NULL
Calvo	NULL
F	NULL
,	NULL
de	NULL
Thé	NULL
H	NULL
:	NULL
The	NULL
PML	NULL
growth-suppressor	NULL
has	NULL
an	NULL
altered	NULL
expression	NULL
in	NULL
human	NULL
oncogenesis	NULL
.	NULL

Oncogene	NULL
10:1315	NULL
,	NULL
1995	NULL
29	NULL
.	NULL

Everett	NULL
RD	NULL
,	NULL
Maul	NULL
GG	NULL
:	NULL
HSV-1	NULL
IE	NULL
protein	NULL
Vmw110	NULL
causes	NULL
redistribution	NULL
of	NULL
PML	NULL
.	NULL

EMBO	NULL
J	NULL
13:5062	NULL
,	NULL
1994	NULL
30	NULL
.	NULL

Maul	NULL
GG	NULL
,	NULL
Everett	NULL
RD	NULL
:	NULL
The	NULL
nuclear	NULL
location	NULL
of	NULL
PML	NULL
,	NULL
a	NULL
cellular	NULL
member	NULL
of	NULL
the	NULL
C3HC4	NULL
zinc-binding	NULL
domain	NULL
protein	NULL
family	NULL
,	NULL
is	NULL
rearranged	NULL
during	NULL
herpes	NULL
simplex	NULL
virus	NULL
infection	NULL
by	NULL
the	NULL
C3HC4	NULL
viral	NULL
protein	NULL
ICPO	NULL
.	NULL

J	NULL
Gen	NULL
Virol	NULL
75:1223	NULL
,	NULL
1994	NULL
31	NULL
.	NULL

Lavau	NULL
C	NULL
,	NULL
Marchio	NULL
A	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Jansen	NULL
J	NULL
,	NULL
Falini	NULL
B	NULL
,	NULL
Lebon	NULL
3935	NULL
P	NULL
,	NULL
Grosveld	NULL
F	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Pelicci	NULL
PG	NULL
,	NULL
Dejan	NULL
A	NULL
:	NULL
The	NULL
PML	NULL
gene	NULL
is	NULL
a	NULL
primary	NULL
target	NULL
for	NULL
interferon	NULL
.	NULL

Oncogene	NULL
11:871	NULL
,	NULL
1995	NULL
32	NULL
.	NULL

Cassatella	NULL
MA	NULL
,	NULL
Capelli	NULL
R	NULL
,	NULL
Della	NULL
Bianca	NULL
V	NULL
,	NULL
Grzeskowiak	NULL
M	NULL
,	NULL
Dusi	NULL
S	NULL
,	NULL
Berton	NULL
G	NULL
:	NULL
Interferon-gamma	NULL
activates	NULL
human	NULL
neutrophil	NULL
oxygen	NULL
metabolism	NULL
and	NULL
exocytosis	NULL
,	NULL
Immunology	NULL
63:499	NULL
,	NULL
1988	NULL
33	NULL
.	NULL

Cassatella	NULL
MA	NULL
,	NULL
Della	NULL
Bianca	NULL
V	NULL
,	NULL
Berton	NULL
G	NULL
,	NULL
Rossi	NULL
F	NULL
:	NULL
Activation	NULL
by	NULL
gamma	NULL
interferon	NULL
of	NULL
human	NULL
macrophage	NULL
capability	NULL
to	NULL
produce	NULL
toxic	NULL
oxygen	NULL
molecules	NULL
is	NULL
accompanied	NULL
by	NULL
decreased	NULL
km	NULL
of	NULL
the	NULL
superoxide-generating	NULL
NADPH	NULL
oxidase	NULL
.	NULL

Biochem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
132:908	NULL
,	NULL
1985	NULL
34	NULL
.	NULL

Chomezynski	NULL
P	NULL
,	NULL
Sacchi	NULL
N	NULL
:	NULL
Single-step	NULL
method	NULL
of	NULL
RNA	NULL
isolation	NULL
by	NULL
acid	NULL
guanidinium	NULL
thiocyanate-phenol-chloroform	NULL
extraction	NULL
.	NULL

Anal	NULL
Biochem	NULL
162:156	NULL
,	NULL
1987	NULL
35	NULL
.	NULL

Feinberg	NULL
AP	NULL
,	NULL
Vogelstein	NULL
B	NULL
:	NULL
A	NULL
technique	NULL
for	NULL
radiolabeling	NULL
DNA	NULL
restriction	NULL
endonuclease	NULL
fragments	NULL
to	NULL
high	NULL
specific	NULL
activity	NULL
.	NULL

Anal	NULL
Biochem	NULL
132:6	NULL
,	NULL
1983	NULL
36	NULL
.	NULL

Fagioli	NULL
M	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Venturini	NULL
L	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Simeone	NULL
A	NULL
,	NULL
Acampora	NULL
D	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
Alternative	NULL
splicing	NULL
of	NULL
PML	NULL
transcripts	NULL
predicts	NULL
coexpression	NULL
of	NULL
several	NULL
carboxy-terminally	NULL
different	NULL
protein	NULL
isoforms	NULL
.	NULL

Oncogene	NULL
7:1083	NULL
,	NULL
1992	NULL
37	NULL
.	NULL

Cleveland	NULL
DW	NULL
,	NULL
Lopata	NULL
MA	NULL
,	NULL
MacDonald	NULL
RJ	NULL
,	NULL
Cowan	NULL
NJ	NULL
,	NULL
Rut-ter	NULL
WJ	NULL
,	NULL
Kirschner	NULL
MW	NULL
:	NULL
Number	NULL
and	NULL
evolutionary	NULL
conservation	NULL
of	NULL
a-	NULL
and	NULL
3-tubulin	NULL
and	NULL
cytoplasmic	NULL
/3-	NULL
and	NULL
y-actin	NULL
genes	NULL
using	NULL
specific	NULL
cloned	NULL
c-DNA	NULL
probes	NULL
.	NULL

Cell	NULL
20:95	NULL
,	NULL
1980	NULL
38	NULL
.	NULL

Flenghi	NULL
L	NULL
,	NULL
Fagioli	NULL
M	NULL
Tomassoni	NULL
L	NULL
,	NULL
Pileri	NULL
S	NULL
,	NULL
Gambacorta	NULL
M	NULL
,	NULL
Pacini	NULL
R	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Casini	NULL
T	NULL
,	NULL
Ferrucci	NULL
PF	NULL
,	NULL
Martelli	NULL
MF	NULL
,	NULL
Pelicci	NULL
PG	NULL
,	NULL
Falini	NULL
B	NULL
:	NULL
Characterization	NULL
of	NULL
a	NULL
new	NULL
monoclonal	NULL
antibody	NULL
(	NULL
PG-M3	NULL
)	NULL
directed	NULL
against	NULL
the	NULL
aminoterminal	NULL
portion	NULL
of	NULL
the	NULL
PML	NULL
gene	NULL
product	NULL
:	NULL
Immunocytochemical	NULL
evidence	NULL
for	NULL
high	NULL
expression	NULL
of	NULL
PML	NULL
proteins	NULL
on	NULL
activated	NULL
macrophages	NULL
,	NULL
endothelial	NULL
cells	NULL
,	NULL
and	NULL
epithelia	NULL
.	NULL

Blood	NULL
85:1871	NULL
,	NULL
1995	NULL
39	NULL
.	NULL

Seale	NULL
JRC	NULL
,	NULL
Varma	NULL
S	NULL
,	NULL
Swirsky	NULL
DM	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Goldman	NULL
JM	NULL
,	NULL
Cross	NULL
NCP	NULL
:	NULL
Quantification	NULL
of	NULL
PML-RARa	NULL
transcripts	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
:	NULL
Explanation	NULL
for	NULL
the	NULL
lack	NULL
of	NULL
sensitivity	NULL
of	NULL
RT-	NULL
PCR	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
minimal	NULL
residual	NULL
disease	NULL
and	NULL
induction	NULL
of	NULL
the	NULL
leukemia	NULL
specific	NULL
mRNA	NULL
by	NULL
alpha	NULL
interferon	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
(	NULL
in	NULL
press	NULL
)	NULL
40	NULL
.	NULL

Lanotte	NULL
M	NULL
,	NULL
Martin-Thouvenin	NULL
V	NULL
,	NULL
Najman	NULL
S	NULL
,	NULL
Balerini	NULL
P	NULL
,	NULL
Va-lensi	NULL
F	NULL
,	NULL
Berger	NULL
R	NULL
:	NULL
NB4	NULL
,	NULL
a	NULL
maturation	NULL
inducible	NULL
cell	NULL
line	NULL
with	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
marker	NULL
isolated	NULL
from	NULL
a	NULL
human	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
M3	NULL
)	NULL
.	NULL

Blood	NULL
77:1080	NULL
,	NULL
1991	NULL
41	NULL
.	NULL

Ahn	NULL
MJ	NULL
,	NULL
Nason-Burchenal	NULL
K	NULL
,	NULL
Moasser	NULL
M	NULL
,	NULL
Dmitrovsky	NULL
E	NULL
:	NULL
Growth	NULL
suppression	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
having	NULL
increased	NULL
expression	NULL
of	NULL
the	NULL
non-rearranged	NULL
alleles	NULL
:	NULL
RARa	NULL
or	NULL
PML	NULL
.	NULL

Oncogene	NULL
10:2307	NULL
,	NULL
1995	NULL
42	NULL
.	NULL

Denizot	NULL
F	NULL
,	NULL
Lang	NULL
R	NULL
:	NULL
Rapid	NULL
colorimetric	NULL
assay	NULL
for	NULL
cell	NULL
growth	NULL
and	NULL
survival	NULL
,	NULL
J	NULL
Immunol	NULL
Methods	NULL
89:271	NULL
,	NULL
1986	NULL
43	NULL
.	NULL

Daniel	NULL
MT	NULL
,	NULL
Koken	NULL
M	NULL
,	NULL
Romagne	NULL
O	NULL
,	NULL
Barbery	NULL
S	NULL
,	NULL
Bazarbachi	NULL
A	NULL
,	NULL
Stadler	NULL
M	NULL
,	NULL
Guillemin	NULL
MC	NULL
,	NULL
Degos	NULL
L	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
de	NULL
The	NULL
H	NULL
:	NULL
PML	NULL
protein	NULL
expression	NULL
in	NULL
hematopoietic	NULL
and	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
.	NULL

Blood	NULL
82:1858	NULL
,	NULL
1993	NULL
44	NULL
.	NULL

Bollag	NULL
W	NULL
,	NULL
Peck	NULL
R	NULL
:	NULL
Modulation	NULL
of	NULL
growth	NULL
and	NULL
differentiation	NULL
by	NULL
combined	NULL
retinoids	NULL
and	NULL
cytokines	NULL
in	NULL
cancer	NULL
,	NULL
in	NULL
Hong	NULL
WK	NULL
,	NULL
Lotan	NULL
R	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Retinoids	NULL
in	NULL
Oncology	NULL
.	NULL

New	NULL
york	NULL
,	NULL
NY	NULL
,	NULL
Marcel	NULL
Dekker	NULL
,	NULL
1993	NULL
,	NULL
p	NULL
89	NULL
45	NULL
.	NULL

Hemmi	NULL
H	NULL
,	NULL
Breitman	NULL
TR	NULL
:	NULL
Combination	NULL
of	NULL
recombinant	NULL
human	NULL
interferons	NULL
and	NULL
retinoic	NULL
acid	NULL
synergistically	NULL
induce	NULL
differentiation	NULL
of	NULL
the	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
HL-60	NULL
.	NULL

Blood	NULL
69:501	NULL
,	NULL
1987	NULL
46	NULL
.	NULL

Trinchieri	NULL
G	NULL
,	NULL
Rosen	NULL
M	NULL
,	NULL
Perussia	NULL
B	NULL
:	NULL
Retinoic	NULL
acid	NULL
cooperates	NULL
with	NULL
tumor	NULL
necrosis	NULL
factor	NULL
and	NULL
immune	NULL
interferon	NULL
in	NULL
inducing	NULL
differentiation	NULL
and	NULL
growth	NULL
inhibition	NULL
of	NULL
the	NULL
human	NULL
promyelocytic	NULL
leukemic	NULL
cell	NULL
line	NULL
HL-60	NULL
.	NULL

Blood	NULL
69:1218	NULL
,	NULL
1987	NULL
47	NULL
.	NULL

Kohlhepp	NULL
EA	NULL
,	NULL
Condon	NULL
ME	NULL
,	NULL
Hamburger	NULL
AW	NULL
:	NULL
Recombinant	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3936	NULL
human	NULL
interferon	NULL
a	NULL
enhancement	NULL
of	NULL
retinoic-acid-induced	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
.	NULL

Exp	NULL
Hematol	NULL
15:414	NULL
,	NULL
1987	NULL
48	NULL
.	NULL

Ho	NULL
CK	NULL
:	NULL
Synergistic	NULL
anticellular	NULL
effect	NULL
of	NULL
a	NULL
combination	NULL
of	NULL
#	NULL
-interferon	NULL
and	NULL
retinoic	NULL
acid	NULL
against	NULL
U937	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
45:5348	NULL
,	NULL
1985	NULL
49	NULL
.	NULL

Chelbi-Alix	NULL
MK	NULL
,	NULL
Pelicano	NULL
L	NULL
,	NULL
Quignon	NULL
F	NULL
,	NULL
Kiken	NULL
MHM	NULL
,	NULL
Venturini	NULL
L	NULL
,	NULL
Stadler	NULL
M	NULL
,	NULL
Pavlovic	NULL
J	NULL
,	NULL
Degos	NULL
L	NULL
,	NULL
de	NULL
Thé	NULL
H	NULL
:	NULL
Induction	NULL
of	NULL
the	NULL
PML	NULL
protein	NULL
by	NULL
interferons	NULL
in	NULL
normal	NULL
and	NULL
APL	NULL
cells	NULL
.	NULL

Leukemia	NULL
9:2027	NULL
,	NULL
1995	NULL
50	NULL
.	NULL

Stadler	NULL
M	NULL
,	NULL
Chelbi-Alix	NULL
MK	NULL
,	NULL
Koken	NULL
MHM	NULL
,	NULL
Venturini	NULL
L	NULL
,	NULL
Lee	NULL
C	NULL
,	NULL
Sab	NULL
A	NULL
,	NULL
Quignon	NULL
F	NULL
,	NULL
Pelicano	NULL
L	NULL
,	NULL
Guillemin	NULL
M-C	NULL
,	NULL
Schindler	NULL
C	NULL
,	NULL
de	NULL
The	NULL
H	NULL
:	NULL
Transcriptional	NULL
induction	NULL
of	NULL
the	NULL
PML	NULL
growth	NULL
suppressor	NULL
gene	NULL
by	NULL
interferons	NULL
is	NULL
mediated	NULL
through	NULL
an	NULL
ISRE	NULL
and	NULL
a	NULL
GAS	NULL
element	NULL
.	NULL

Oncogene	NULL
11:2565,1996	NULL
51	NULL
.	NULL

Koller	NULL
E	NULL
,	NULL
Krieger	NULL
O	NULL
,	NULL
Kasparu	NULL
H	NULL
,	NULL
Lutz	NULL
D	NULL
:	NULL
Restoration	NULL
of	NULL
all	NULL
NASON-BURCHENAL	NULL
ET	NULL
AL	NULL
trans	NULL
retinoic	NULL
acid	NULL
sensitivity	NULL
by	NULL
interferon	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Lancet	NULL
338:1	NULL
154	NULL
,	NULL
1991	NULL
52	NULL
.	NULL

Warrell	NULL
RP	NULL
Jr	NULL
:	NULL
Retinoid	NULL
resistance	NULL
.	NULL

Lancet	NULL
341:126	NULL
,	NULL
1993	NULL
(	NULL
let-ter	NULL
)	NULL
53	NULL
.	NULL

Dermime	NULL
S	NULL
,	NULL
Grignani	NULL
FR	NULL
,	NULL
Clerici	NULL
M	NULL
,	NULL
Nervi	NULL
C	NULL
,	NULL
Sozzi	NULL
G	NULL
,	NULL
Talamo	NULL
GP	NULL
,	NULL
Marches	NULL
E	NULL
,	NULL
Formelli	NULL
F	NULL
,	NULL
Parmiani	NULL
G	NULL
,	NULL
Pelicci	NULL
PG	NULL
,	NULL
Gambacorti-Passerini	NULL
C	NULL
:	NULL
Occurrence	NULL
of	NULL
resistance	NULL
to	NULL
retinoic	NULL
acid	NULL
in	NULL
the	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
NB306	NULL
is	NULL
associated	NULL
with	NULL
altered	NULL
expression	NULL
of	NULL
the	NULL
PML/RARa	NULL
protein	NULL
.	NULL

Blood	NULL
82:1573	NULL
,	NULL
1993	NULL
54	NULL
.	NULL

Licht	NULL
JD	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Goy	NULL
A	NULL
,	NULL
Chen	NULL
A	NULL
,	NULL
Scott	NULL
A	NULL
,	NULL
Head	NULL
DR	NULL
,	NULL
Michaux	NULL
JL	NULL
,	NULL
Wu	NULL
Y	NULL
,	NULL
DeBlasio	NULL
A	NULL
,	NULL
Miller	NULL
WH	NULL
,	NULL
Zelenetz	NULL
AD	NULL
,	NULL
Willman	NULL
CL	NULL
,	NULL
Chen	NULL
Z	NULL
,	NULL
Chen	NULL
SJ	NULL
,	NULL
Zelent	NULL
A	NULL
,	NULL
Macintyre	NULL
E	NULL
,	NULL
Veil	NULL
A	NULL
,	NULL
Cortes	NULL
J	NULL
,	NULL
Kantarjia	NULL
H	NULL
,	NULL
Waxman	NULL
S	NULL
:	NULL
Clinical	NULL
and	NULL
molecular	NULL
characterization	NULL
of	NULL
a	NULL
rare	NULL
syndrome	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
associated	NULL
with	NULL
translocation	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
.	NULL

Blood	NULL
85:1083	NULL
,	NULL
1995	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blO	NULL
0d	NULL
1996	NULL
88	NULL
:	NULL
3926-3936	NULL
Interferon	NULL
augments	NULL
PML	NULL
and	NULL
PML/RAR	NULL
alpha	NULL
expression	NULL
in	NULL
normal	NULL
myeloid	NULL
and	NULL
acute	NULL
promyelocytic	NULL
cells	NULL
and	NULL
cooperates	NULL
with	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
to	NULL
induce	NULL
maturation	NULL
of	NULL
a	NULL
retinoid-resistant	NULL
promyelocytic	NULL
cell	NULL
line	NULL
A	NULL
_	NULL
48	NULL
o	NULL
6	NULL
'	NULL
t	NULL
\se	NULL
@	NULL
.	NULL

/	NULL
{	NULL
®	NULL
K	NULL
Nason-Burchenal	NULL
,	NULL
D	NULL
Gandini	NULL
,	NULL
M	NULL
Botto	NULL
,	NULL
J	NULL
Allopenna	NULL
,	NULL
JR	NULL
Seale	NULL
,	NULL
NC	NULL
Cross	NULL
,	NULL
JM	NULL
Goldman	NULL
,	NULL
E	NULL
Dmitrovsky	NULL
and	NULL
PP	NULL
Pandolfi	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/88/10/3926.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

